Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Oct. 28, 2022 | |
Cover [Abstract] | ||
Entity Registrant Name | INNOVIVA, INC. | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-30319 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3265960 | |
Entity Address, Address Line One | 1350 Old Bayshore Highway Suite 400 | |
Entity Address, City or Town | Burlingame | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94010 | |
City Area Code | 650 | |
Local Phone Number | 238-9600 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | INVA | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 69,783,185 | |
Entity Central Index Key | 0001080014 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 300,789 | $ 201,525 |
Short-term marketable securities | 282 | 0 |
Accounts receivable | 6,743 | 0 |
Receivables from collaboration arrangement | 65,606 | 110,711 |
Inventory | 70,807 | 0 |
Prepaid expenses | 7,932 | 1,367 |
Other current assets | 2,432 | 70 |
Total current assets | 454,591 | 313,673 |
Property and equipment, net | 165 | 12 |
Equity and long-term investments | 489,111 | 483,845 |
Capitalized fees paid to a related party, net | 101,062 | 111,430 |
Right-of-use assets | 3,679 | 97 |
Goodwill | 15,995 | 0 |
Intangible assets | 258,489 | 0 |
Deferred tax assets, net | 0 | 17,327 |
Other assets | 4,620 | 11 |
Total assets | 1,327,712 | 926,395 |
Current liabilities: | ||
Accounts payable | 3,805 | 27 |
Accrued personnel-related expenses | 6,473 | 619 |
Accrued interest payable | 5,702 | 4,152 |
Deferred revenue | 2,849 | 0 |
Convertible subordinated notes due 2023, net of issuance costs | 96,131 | 0 |
Income tax payable | 33,804 | 0 |
Other accrued liabilities | 15,120 | 1,009 |
Total current liabilities | 163,884 | 5,807 |
Long-term debt, net of discount and issuance costs | 443,679 | 394,653 |
Other long-term liabilities | 78,421 | 0 |
Deferred tax liabilities | 360 | 0 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding | 0 | 0 |
Common stock: $0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of September 30, 2022 and December 31, 2021 respectively | 698 | 696 |
Treasury stock: at cost, 32,005 shares as of September 30, 2022 and December 31, 2021, respectively | (393,829) | (393,829) |
Additional paid-in capital | 1,171,096 | 1,264,024 |
Accumulated deficit | (136,597) | (456,148) |
Total Innoviva stockholders' equity | 641,368 | 414,743 |
Noncontrolling interest | 0 | 111,192 |
Total stockholders' equity | 641,368 | 525,935 |
Total liabilities and stockholders' equity | $ 1,327,712 | $ 926,395 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 230,000 | 230,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 69,776,000 | 69,566,000 |
Common stock, shares outstanding | 69,776,000 | 69,566,000 |
Treasury stock, shares | 32,005,000 | 32,005,000 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Total revenue | $ 67,257 | $ 97,862 | $ 265,536 | $ 284,186 |
Expenses: | ||||
Selling, general and administrative | 27,810 | 2,860 | 46,084 | 13,074 |
Research and development | 11,725 | 449 | 31,447 | 536 |
Amortization of intangible assets | 1,511 | 0 | 1,511 | 0 |
Gain on sale of Theravance Respiratory Company, LLC ("TRC") | (266,696) | 0 | (266,696) | 0 |
Loss on extinguishment of debt | 0 | 0 | 20,662 | 0 |
Changes in fair values of equity and long-term investments, net | (130) | (33,613) | 67,881 | (133,973) |
Interest and dividend income | (2,135) | (453) | (3,181) | (503) |
Interest expense | 5,096 | 4,790 | 11,761 | 14,229 |
Other expense (income), net | (28) | 652 | 750 | 2,036 |
Total expenses | (219,167) | (25,315) | (86,101) | (104,601) |
Income before income taxes | 286,424 | 123,177 | 351,637 | 388,787 |
Income tax expense net | 57,077 | 20,531 | 63,061 | 65,600 |
Net income (loss) | 229,347 | 102,646 | 288,576 | 323,187 |
Net income (loss) attributable to noncontrolling interests | (36,176) | 30,208 | 6,341 | 67,678 |
Net income attributable to Innoviva stockholders | $ 265,523 | $ 72,438 | $ 282,235 | $ 255,509 |
Basic net income per share attributable to Innoviva stockholders | $ 3.81 | $ 1.04 | $ 4.05 | $ 2.96 |
Diluted net income per share attributable to Innoviva stockholders | $ 2.80 | $ 0.90 | $ 3.07 | $ 2.63 |
Shares used to compute Innoviva basic and diluted net income per share: | ||||
Shares used to compute basic net income per share | 69,731 | 69,458 | 69,640 | 86,298 |
Shares used to compute diluted net income per share | 95,830 | 81,699 | 95,072 | 98,536 |
Royalty revenue from a related party | ||||
Revenue: | ||||
Total revenue | $ 62,150 | $ 97,862 | $ 260,429 | $ 284,186 |
Net product sales | ||||
Revenue: | ||||
Total revenue | 5,107 | 0 | 5,107 | 0 |
Expenses: | ||||
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets) | $ 3,680 | $ 0 | $ 3,680 | $ 0 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Royalty revenue from a related party | GSK | ||||
Amortization of capitalized fees paid to a related party | $ 3,456 | $ 3,456 | $ 10,368 | $ 10,368 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net Income | $ 229,347 | $ 102,646 | $ 288,576 | $ 323,187 |
Comprehensive income | 229,347 | 102,646 | 288,576 | 323,187 |
Comprehensive income (loss) attributable to noncontrolling interests | (36,176) | 30,208 | 6,341 | 67,678 |
Comprehensive income attributable to Innoviva stockholders | $ 265,523 | $ 72,438 | $ 282,235 | $ 255,509 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common stock | Additional Paid-In Capital | Accumulated Deficit | Treasury Stock | Noncontrolling Interest | Cumulative Effect, Period of Adoption, Adjustment [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment [Member] Accumulated Deficit |
Balance at Dec. 31, 2020 | $ 607,837 | $ 1,014 | $ 1,260,900 | $ (722,002) | $ 0 | $ 67,925 | |||
Balance (in shares) at Dec. 31, 2020 | 101,392,000 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | (21,285) | $ 0 | 0 | 0 | 0 | (21,285) | |||
Equity activity of noncontrolling interest from a consolidated variable interest entity | 8 | 0 | 0 | 0 | 0 | 8 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | (25) | $ 0 | (25) | 0 | 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 16,000 | ||||||||
Stock-based compensation | 451 | $ 0 | 451 | 0 | 0 | 0 | |||
Net income | 109,695 | 0 | 0 | 94,123 | 0 | 15,572 | |||
Balance at Mar. 31, 2021 | 696,681 | $ 1,014 | 1,261,326 | (627,879) | 0 | 62,220 | |||
Balance (in shares) at Mar. 31, 2021 | 101,408,000 | ||||||||
Balance at Dec. 31, 2020 | 607,837 | $ 1,014 | 1,260,900 | (722,002) | 0 | 67,925 | |||
Balance (in shares) at Dec. 31, 2020 | 101,392,000 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 323,187 | ||||||||
Balance at Sep. 30, 2021 | 491,805 | $ 695 | 1,262,438 | (466,493) | $ (393,829) | 88,994 | |||
Balance (in shares) at Sep. 30, 2021 | 69,492,000 | 32,005,000 | |||||||
Balance at Mar. 31, 2021 | 696,681 | $ 1,014 | 1,261,326 | (627,879) | $ 0 | 62,220 | |||
Balance (in shares) at Mar. 31, 2021 | 101,408,000 | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | (20,161) | $ 0 | 0 | 0 | 0 | (20,161) | |||
Equity activity of noncontrolling interest from a consolidated variable interest entity | 8 | 0 | 0 | 0 | 0 | 8 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | 50 | $ 1 | 49 | 0 | 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 92,000 | ||||||||
Repurchase of common stock | (394,149) | $ (320) | 0 | 0 | $ (393,829) | 0 | |||
Repurchase of common stock (in shares) | (32,005,000) | 32,005,000 | |||||||
Stock-based compensation | 470 | $ 0 | 470 | 0 | $ 0 | 0 | |||
Net income | 110,846 | 0 | 0 | 88,948 | 0 | 21,898 | |||
Balance at Jun. 30, 2021 | 393,745 | $ 695 | 1,261,845 | (538,931) | $ (393,829) | 63,965 | |||
Balance (in shares) at Jun. 30, 2021 | 69,495,000 | 32,005,000 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | (4,912) | (4,912) | |||||||
Equity activity of noncontrolling interest from a consolidated variable interest entity | (267) | (267) | |||||||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | 51 | $ 0 | 51 | 0 | $ 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | (3,000) | ||||||||
Stock-based compensation | 542 | $ 0 | 542 | 0 | 0 | 0 | |||
Net income | 102,646 | 0 | 0 | 72,438 | 0 | 30,208 | |||
Balance at Sep. 30, 2021 | 491,805 | $ 695 | 1,262,438 | (466,493) | $ (393,829) | 88,994 | |||
Balance (in shares) at Sep. 30, 2021 | 69,492,000 | 32,005,000 | |||||||
Balance at Jun. 30, 2022 | 565,462 | $ 697 | 1,183,667 | (402,198) | $ (393,829) | 177,125 | |||
Balance (in shares) at Jun. 30, 2022 | 69,706,000 | 32,005,000 | |||||||
Balance at Dec. 31, 2021 | $ 525,935 | $ 696 | 1,264,024 | (456,148) | $ (393,829) | 111,192 | $ (28,123) | $ (65,361) | $ 37,238 |
Balance (in shares) at Dec. 31, 2021 | 69,566,000 | 69,566,000 | 32,005,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | $ (6,507) | $ 0 | 0 | 0 | $ 0 | (6,507) | |||
Fair value of noncontrolling interest in a consolidated variable interest entity | 38,471 | 0 | 0 | 0 | 0 | 38,471 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | 214 | $ 0 | 214 | 0 | 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 28,000 | ||||||||
Stock-based compensation | 954 | $ 0 | 620 | 0 | 0 | 334 | |||
Capped call options associated with convertible senior notes due 2028 | (16,585) | 0 | (16,585) | 0 | 0 | 0 | |||
Net income | 37,858 | 0 | 0 | 15,773 | 0 | 22,085 | |||
Balance at Mar. 31, 2022 | 552,217 | $ 696 | 1,182,912 | (403,137) | $ (393,829) | 165,575 | |||
Balance (in shares) at Mar. 31, 2022 | 69,594,000 | 32,005,000 | |||||||
Balance at Dec. 31, 2021 | $ 525,935 | $ 696 | 1,264,024 | (456,148) | $ (393,829) | 111,192 | $ (28,123) | $ (65,361) | $ 37,238 |
Balance (in shares) at Dec. 31, 2021 | 69,566,000 | 69,566,000 | 32,005,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Accounting Standards Update [Extensible Enumeration] | Accounting Standards Update 2020-06 [Member] | Accounting Standards Update 2020-06 [Member] | Accounting Standards Update 2020-06 [Member] | ||||||
Net income | $ 288,576 | ||||||||
Balance at Sep. 30, 2022 | $ 641,368 | $ 698 | 1,171,096 | (136,597) | $ (393,829) | 0 | |||
Balance (in shares) at Sep. 30, 2022 | 69,776,000 | 69,776,000 | 32,005,000 | ||||||
Balance at Mar. 31, 2022 | $ 552,217 | $ 696 | 1,182,912 | (403,137) | $ (393,829) | 165,575 | |||
Balance (in shares) at Mar. 31, 2022 | 69,594,000 | 32,005,000 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | (9,545) | $ 0 | 0 | 0 | $ 0 | (9,545) | |||
Equity activity of noncontrolling interest from a consolidated variable interest entity | (2) | 0 | 0 | 0 | 0 | (2) | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | 68 | $ 1 | 67 | 0 | 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 112,000 | ||||||||
Conversion of convertible subordinated notes due 2023 | 3 | $ 0 | 3 | 0 | 0 | 0 | |||
Stock-based compensation | 1,350 | 0 | 685 | 0 | 0 | 665 | |||
Net income | 21,371 | 0 | 0 | 939 | 0 | 20,432 | |||
Balance at Jun. 30, 2022 | 565,462 | $ 697 | 1,183,667 | (402,198) | $ (393,829) | 177,125 | |||
Balance (in shares) at Jun. 30, 2022 | 69,706,000 | 32,005,000 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Distributions to noncontrolling interest | (53,759) | $ 0 | 0 | 0 | $ 0 | (53,759) | |||
Derecognition of noncontrolling interests upon sale of TRC | (61,226) | 78 | 0 | (61,304) | |||||
Derecognition of noncontrolling interests upon acquisition of Entasis Therapeutics Holdings Inc. ("Entasis") minority interest | (42,162) | 0 | (14,153) | 0 | 0 | (28,009) | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding | (11) | $ 1 | (12) | 0 | 0 | 0 | |||
Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) | 70,000 | ||||||||
Stock-based compensation | 3,717 | $ 0 | 1,594 | 0 | 0 | 2,123 | |||
Net income | 229,347 | 0 | 0 | 265,523 | 0 | (36,176) | |||
Balance at Sep. 30, 2022 | $ 641,368 | $ 698 | $ 1,171,096 | $ (136,597) | $ (393,829) | $ 0 | |||
Balance (in shares) at Sep. 30, 2022 | 69,776,000 | 69,776,000 | 32,005,000 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities | ||
Net income | $ 288,576 | $ 323,187 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Deferred income tax | 29,258 | 65,600 |
Depreciation and amortization | 12,507 | 10,376 |
Amortization of inventory fair value adjustments included in cost of products sold | 2,743 | 0 |
Stock-based compensation | 6,021 | 1,463 |
Amortization of debt discount and issuance costs | 1,491 | 6,778 |
Amortization of deferred royalty obligation value adjustment | 482 | 0 |
Changes in fair values of equity and long-term investments, net | 66,448 | (132,485) |
Loss on extinguishment of debt | 20,662 | 0 |
Net gain on sale of TRC | (266,696) | 0 |
Other | 995 | (251) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (867) | 0 |
Receivables from collaboration arrangement | 2,385 | (7,340) |
Inventory | 350 | 0 |
Prepaid expenses | 277 | 770 |
Other assets, current | 692 | 328 |
Other assets, non-current | (3,624) | 0 |
Accounts payable | 958 | 23 |
Accrued personnel-related expenses and other accrued liabilities | (1,709) | (533) |
Accrued interest payable | (1,926) | (2,484) |
Income tax payable | 33,804 | 0 |
Net cash provided by operating activities | 192,827 | 265,432 |
Cash flows from investing activities | ||
Purchases of equity and long-term investments | (58,725) | (46,373) |
Purchases of equity investments managed by ISP Fund LP | (92,951) | (178,445) |
Sales of equity investments managed by ISP Fund LP | 24,281 | 21,426 |
Purchase and sales of other investments managed by ISP Fund LP, net | (41,330) | 267,019 |
Purchases of property and equipment | (33) | 0 |
Proceeds from sale of ownership interest in TRC, net | 248,191 | 0 |
Cash acquired through the consolidation of Entasis | 23,070 | 0 |
Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired | (150,459) | 0 |
Net cash (used in) provided by investing activities | (47,956) | 63,627 |
Cash flows from financing activities | ||
Distributions to noncontrolling interests | (69,811) | (46,358) |
Purchase of Entasis noncontrolling interest | (42,395) | 0 |
Repurchase of common stock | 0 | (394,149) |
Repurchase of shares to satisfy tax withholding | (71) | (47) |
Proceeds from issuances of common stock, net | 342 | 123 |
Payment for repurchase of convertible subordinated notes due 2023 | (165,131) | 0 |
Purchases of capped call options associated with convertible senior notes due 2028 | (21,037) | 0 |
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs | 252,536 | 0 |
Net cash used in financing activities | (45,567) | (440,431) |
Net increase (decrease) in cash, cash equivalents and restricted cash | 99,304 | (111,372) |
Cash and cash equivalents at beginning of period | 201,525 | 246,487 |
Cash, cash equivalents and restricted cash at end of period | 300,829 | 135,115 |
Supplemental Disclosure of Cash Flow Information: | ||
Cash paid for interest | 11,736 | 9,933 |
Cash paid for income taxes | 3,859 | 0 |
Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
Cash and cash equivalents | 300,789 | 135,115 |
Restricted cash, included in "Other assets" | 40 | 0 |
Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows | 300,829 | 135,115 |
ASU 2020-06 | ||
Supplemental Disclosure of Non-cash Investing and Financing Activities: | ||
Adoption of ASU 2020-06 | $ 28,123 | $ 0 |
Description of Operations and S
Description of Operations and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Operations and Summary of Significant Accounting Policies | 1. Description of Operations and Summary of Significant Accounting Policies Description of Operations Innoviva, Inc. (referred to as “Innoviva”, the “Company”, or “we” and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR ® /BREO ® ELLIPTA ® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO ® ELLIPTA ® (umeclidinium bromide/ vilanterol, “UMEC/VI”), and up until July 2022, TRELEGY ® ELLIPTA ® (the combination FF/UMEC/VI). We sold our 15 % ownership interest in Theravance Respiratory Company, LLC (“TRC”) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY ® ELLIPTA ® products. Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® as follows: 15 % on the first $ 3.0 billion of annual global net sales and 5 % for all annual global net sales above $ 3.0 billion; and royalties from the sales of ANORO ® ELLIPTA ® , which tier upward at a range from 6.5 % to 10 %. We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (“La Jolla”) on August 22, 2022. Our commercial and marketed products include GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (“SUL-DUR”). Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and, in our opinion, include all adjustments, consisting of all normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022 or any other periods. The accompanying unaudited condensed consolidated financial statements include the accounts of Innoviva, our wholly-owned subsidiaries, and certain variable interest entities (“VIEs”) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income attributable to noncontrolling interest in our unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022, and as amended on March 17, 2022. Factors Affecting Comparability Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, “Consolidated Entities and Acquisitions”. • Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining minority interest in Entasis on July 11, 2022, • Sale of our 15 % ownership interest in Theravance Respiratory Company, LLC (“TRC”) on July 20, 2022, and • Acquisition of La Jolla on August 22, 2022. Prior Period Immaterial Correction Subsequent to the issuance of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021, the Company identified that (i) purchases of equity investments managed by ISP Fund LP for $ 178.4 million, (ii) sales of equity investments managed by ISP Fund LP for $ 21.4 million, and (iii) purchase and sales of other investments managed by ISP Fund LP, net for $ 267.0 million were incorrectly included in the unaudited condensed consolidated statement of cash flows within the distribution of equity and long-term investments line item. The Company has corrected the presentation in the accompanying unaudited condensed consolidated statement of cash flows for the nine months ended September 30, 2021 from amounts previously reported to present such line items separately. The correction did not impact total cash flows from investing activities or the unaudited condensed consolidated balance sheet, statement of income, or statement of comprehensive income for the relevant period. Management assessed the correction on a quantitative and qualitative basis and determined that it is immaterial to the prior period unaudited condensed consolidated financial statements. Use of Management’s Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Concentrations of Credit Risk and of Significant Suppliers and Partner Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits. We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (“API”) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products. Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts’ or investors’ expectations, due to a number of important factors. We also started recognizing revenue from product sales as a result of our acquisition of La Jolla. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. Three of our customers each comprise 10 % or more of our net product sales and they account for 32 %, 32 % and 29 %, respectively, of our net product sales from the time of La Jolla ’ s acquisition to September 30, 2022. These same customers account for 34 %, 23 % and 35 %, respectively, of our receivables from net product sales, which is included in “Accounts receivables, net” in our unaudited consolidated balance sheet as of September 30, 2022. Refer to Item 1A. “Risk Factors” disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and to the supplemental risk factors detailed in our Form 8-K filed on August 23, 2022 for further detail. Segment Reporting We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA ® and XERAVA ® . Our long-term assets are located within the United States. Variable Interest Entities We evaluate our ownership, contractual and other interest in entities to determine if they are a VIE. We evaluate whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluation, if we determine we are the primary beneficiary of a VIE, we consolidate the entity in our financial statements. Business Combination When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred. Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset’s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives. Cash and Cash Equivalents We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value. Accounts Receivable, Net Accounts receivable, net are recorded net of estimates for prompt-pay discounts, chargebacks, returns, rebates, and administrative fees. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Inventory Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales . Goodwill and Intangible Assets Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite lives are subject to impairment testing at least annually or more frequently if indicators for potential impairment exist. Intangible assets with definite lives are amortized on a straight-line basis over the remaining useful life of the intangible asset. These assets are tested for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Significant judgments are involved in determining if an indicator of impairment has occurred. Operating Leases We account for our leases under ASC 842, Leases . Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term. Equity and Long-Term Investments We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our unaudited condensed consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships. We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity and long-term investments, net within the unaudited condensed consolidated statements of income. If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, Investments - Equity Securities . This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which prevents us from having control and access to the contributions and related investments. These investments are classified as long-term investments on the unaudited condensed consolidated balance sheets. Revenue Recognition Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied. Royalty Revenue from Collaboration Arrangement We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK. Revenue from Product Sales Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include: • Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers. • Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers. • Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. • Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. • Administrative Fees: We pay administrative fees to GPOs for services and access to data. Additionally, we pay an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers. We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly. Research and Development Costs Research and development costs are expensed in the period that services are rendered or goods are received. Research and development costs consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities. Interest Expense on Deferred Royalty Obligation Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA ® . Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 6, “Financial Instruments and Fair Value Measurements” for more information. Accounting Pronouncement Adopted by the Company In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (“EPS”) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $ 37.2 million, a reduction to additional paid-in capital of $ 65.4 million, an increase to the balance of the notes by an aggregate amount of $ 35.6 million, and an increase to deferred tax assets of $ 7.4 million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 10, “Debt” for more information. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers . During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our unaudited, condensed consolidated financial statements. |
Net Income Per Share
Net Income Per Share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | 2. Net Income Per Share Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the “2023 Notes”), our convertible senior notes due 2025 (the “2025 Notes”) and our convertible senior notes due 2028 (the “2028 Notes”) using the if-converted method. The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of the 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $ 17.26 per share, there wa s no dilutive effect of the assumed conversion premium for the three and nine months ended September 30, 2021. The dilutive EPS of the notes was approximatel y $ 0.37 and $ 0.41 per share, respectively, using the if-converted method for the three and nine months ended September 30, 2022 as a result of the adoption of ASU 2020-06. The following table shows the computation of basic and diluted net income per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands except per share data) 2022 2021 2022 2021 Numerator: Net income attributable to Innoviva stockholders, basic $ 265,523 $ 72,438 $ 282,235 $ 255,509 Add: interest expense on 2023 Notes 412 1,186 2,003 3,553 Add: interest expense on 2025 Notes 994 — 3,533 — Add: interest expense on 2028 Notes 1,769 — 3,862 — Net income attributable to Innoviva stockholders, diluted $ 268,698 $ 73,624 $ 291,633 $ 259,062 Denominator: Weighted-average shares used to compute basic net income 69,731 69,458 69,640 86,298 Dilutive effect of 2023 Notes 4,866 12,189 6,629 12,189 Dilutive effect of 2025 Notes 11,150 — 11,150 — Dilutive effect of 2028 Notes 9,955 — 7,559 — Dilutive effect of options and awards granted under equity 128 52 94 49 Weighted-average shares used to compute diluted net income 95,830 81,699 95,072 98,536 Net income per share attributable to Innoviva stockholders Basic $ 3.81 $ 1.04 $ 4.05 $ 2.96 Diluted $ 2.80 $ 0.90 $ 3.07 $ 2.63 Anti-Dilutive Securities The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti-dilutive for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Outstanding options and awards granted under equity incentive 705 891 577 1,048 Outstanding stock warrant 526 — 177 — Total 1,231 891 754 1,048 |
Revenue Recognition
Revenue Recognition | 9 Months Ended |
Sep. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | 3. Revenue Recognition Net Revenue from Collaboration Arrangement On July 13, 2022, Innoviva’s wholly-owned subsidiary, Innoviva TRC Holdings, LLC (“ITH”) entered into an equity purchase agreement (“TRC Equity Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”) to sell our ownership interest in Theravance Respiratory Company, LLC (“TRC”). As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive 15 % of royalty payments made by GSK stemming from sales of TRELEGY ® ELLIPTA ® . We retained our royalty rights with respect to RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . Net revenue recognized under our GSK Agreements was as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Royalties $ 55,663 $ 54,092 $ 170,753 $ 176,398 Royalties 9,943 11,641 28,015 34,101 Royalties — 35,585 72,029 84,055 Total royalties from a related party 65,606 101,318 270,797 294,554 Less: amortization of capitalized fees ( 3,456 ) ( 3,456 ) ( 10,368 ) ( 10,368 ) Royalty revenue from GSK $ 62,150 $ 97,862 $ 260,429 $ 284,186 Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Net Product Sales Our net product sales of $ 5.1 million, consisting of net sales of GIAPREZA ® and XERAVA ® for $ 3.8 million and $ 1.3 million, respectively, were recognized from the date of our acquisition of La Jolla, which occurred on August 22, 2022, to September 30, 2022 . |
License and Collaboration Arran
License and Collaboration Arrangements | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
License and Collaboration Arrangements | 4. License and Collaboration Arrangements Out-License Agreements Zai Lab Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (“Zai Lab”) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (“the Zai Agreement”). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement. We are eligible to receive up to an aggregate of $ 91.0 million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. During the three months ended September 30, 2022, no revenue was recognized under the Zai Agreement. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded from the date of acquisition of Entasis to September 30, 2022 are not material. GARDP Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (“GARDP”) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (“the GARDP Collaboration Agreement”). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts from the date of acquisition of Entasis to September 30, 2022 are not material. In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP’s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (“EMA”). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories. PAION AG Pursuant to the PAION AG (“PAION”) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA ® and XERAVA ® in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). We are entitled to receive potential commercial milestone payments of up to $ 109.5 million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA ® and XERAVA ® in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA ® and XERAVA ® in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to September 30, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to September 30, 2022 was not material. La Jolla also entered into the PAION commercial supply agreement (the “PAION Supply Agreement”) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA ® and XERAVA ® through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. We have not recognized any cost reimbursements under this agreement from the date of acquisition of La Jolla to September 30, 2022. Everest Medicines Limited Pursuant to the Everest Medicines Limited (“Everest”) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA ® for the treatment of complicated intra-abdominal infections (“cIAI”) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). We are eligible to receive an additional $ 8.0 million regulatory milestone payment and up to an aggregate of $ 20.0 million in sales milestone payments. We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. We have not recognized any revenue from Everest related to regulatory and sales milestones from the date of acquisition of La Jolla to September 30, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to September 30, 2022 was not material. A new drug application (“NDA”) was submitted with the China National Medical Products Administration (“NMPA”) for XERAVA ® for the treatment of cIAI in patients in China in 2021. XERAVA ® was approved in Singapore by the Health Science Authority in 2020. La Jolla also entered into the Everest commercial supply agreement (the “Everest Supply Agreement”) whereby La Jolla will supply Everest a minimum quantity of XERAVA ® through December 31, 2023 and will transfer to Everest certain XERAVA ® -related manufacturing know-how. We will be reimbursed for direct and certain indirect manufacturing costs at 110 % of cost through December 31, 2023. We recognized $ 2.8 million partial prepayment for XERAVA ® that is expected to be delivered to Everest as deferred revenue as of September 30, 2022. In-License Agreements George Washington University Pursuant to the George Washington University (“GW”) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA ® , including the exclusive rights to certain issued patents and patent applications covering GIAPREZA ® . Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA ® . We are obligated to pay a 6 % royalty on net sales of GIAPREZA ® and 15 % on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA ® . From the date of acquisition of La Jolla to September 30, 2022, the amounts recognized under this agreement were not material. Harvard University Pursuant to the Harvard University (“Harvard”) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA ® , including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA ® . For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $ 15.1 million upon the achievement of certain clinical development and regulatory milestones; (ii) a 5 % royalty on direct U.S. net sales of XERAVA ® ; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA ® , starting at a minimum royalty rate of 4.5 %, with step-ups to a maximum royalty of 7.5 % based on the achievement of annual net product sales thresholds; and (iv) 20 % on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA ® . From the date of acquisition of La Jolla to September 30, 2022, amounts recognized under this agreement were not material. Paratek Pharmaceuticals, Inc. Pursuant to the Paratek Pharmaceuticals, Inc. (“Paratek”) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA ® , including non-exclusive rights to certain issued patents and patent applications covering XERAVA ® . We are obligated to pay Paratek a 2.25 % royalty based on direct U.S. net sales of XERAVA ® . Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA ® and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023 . From the date of acquisition of La Jolla to September 30, 2022 , amounts recognized under this agreement were not material. |
Consolidated Entities and Acqui
Consolidated Entities and Acquisitions | 9 Months Ended |
Sep. 30, 2022 | |
Consolidated Entities | |
Consolidated Entities and Acquisitions | 5. Consolidated Entities and Acquisitions Consolidated Entities Theravance Respiratory Company, LLC Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity. We held 15 % ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY ® ELLIPTA ® by GSK. As discussed in Note 3, “ Revenue Recognition”, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $ 277.5 million in cash from Royalty Pharma. We are also entitled to receive up to $ 50.0 million in contingent sales-based milestone payments in the future. As part of the closing of the transaction, we also received our portion of TRC’s remaining cash balance of $ 4.4 million from Royalty Pharma rather than through a cash distribution from TRC. Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics, Inc., ImaginAb, Inc., Gate Neurosciences, Inc. and Nanolive SA, which had a total carrying value of $ 39.4 million, to ITH. The summarized financial information of TRC as of December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows: Balance sheet December 31, (In thousands) 2021 Assets Cash and cash equivalents $ 50,713 Receivables from collaboration arrangement 42,492 Prepaid expenses and other current assets 71 Equity and long-term investments 37,695 Total assets $ 130,971 Liabilities and LLC Members’ Equity Current liabilities $ 252 LLC members’ equity 130,719 Total liabilities and LLC members’ equity $ 130,971 Income statements Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 (1) 2021 2022 (2) 2021 Royalty revenue from a related party $ — $ 35,585 $ 72,029 $ 84,055 Operating expenses ( 5 ) 194 332 3,811 Income from operations 5 35,391 71,697 80,244 Other income, net — — 10 — Realized loss ( 39,386 ) — ( 39,386 ) — Income tax expense, net — — 1 — Changes in fair values of equity and long-term — 148 ( 8,884 ) ( 589 ) Net income (loss) $ ( 39,381 ) $ 35,539 $ 23,438 $ 79,655 (1) Three months ended September 30, 2022 represents the period from July 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. (2) Nine months ended September 30, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. ISP Fund LP We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities. The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners’ capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period. The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations. In May 2021, Strategic Partners received a distribution of $ 110.0 million from the Partnership to provide funding to Innoviva for a strategic repurchase of shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $ 110.0 million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a 36-month lock up period from the contribution date. As of September 30, 2022, we held approximately 100 % of the economic interest of the Partnership. As of September 30, 2022 and December 31, 2021, total assets of the Part nership were $ 289.8 million and $ 195.8 million, respectively, of which the majority was attributable to equity, debt and long-term investments. As of September 30, 2022 and December 31, 2021, total liabilities were $ 0.2 million and $ 0.2 million, respectively . The partnership’s assets can only be used to settle its own obligations. During the three and nine months ended September 30, 2022, we record ed $ 0.3 million and $ 1.0 million, r espectively, of net investment-related expenses incurred by the Partnership, a nd $ 10.5 million and $ 14.9 million, respectively, of net negative changes in fair values of equity and long-term investments on the unaudited condensed consolidated statements of income. During the three and nine months ended September 30, 2021 , we recorded $ 0.2 million and $ 1.5 million, respectively, of net investment-related expenses incurred by the Partnership, and $ 10.1 million and $ 30.6 million, respectively, of net positive changes in fair values of equity and long-term investments on the unaudited condensed consolidated statements of income. Acquisitions Entasis Therapeutics Holdings Inc. We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis is an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. During the second quarter of 2020, we purchased 14,000,000 shares of common stock as well as warrants to purchase 14,000,000 additional shares of common stock of Entasis for approximately $ 35.0 million in cash. During the third quarter of 2020, we purchased 4,672,897 shares of Entasis common stock as well as warrants to purchase 4,672,897 additional shares of its common stock for approximately $ 12.5 million in cash. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva has the right to designate two members to Entasis’ board. During the second quarter of 2021, Innoviva’s wholly-owned subsidiary, Innoviva Strategic Opportunities, LLC (“ISO”) entered into a securities purchase agreement with Entasis to acquire 10,000,000 shares of Entasis common stock and warrants to purchase 10,000,000 additional shares of Entasis common stock for approximately $ 20.0 million. The fair value of Entasis’ common stock was measured based on its closing market price at each balance sheet date. The warrants had an exercise price of $ 2.50 per share and $ 2.675 per share for those warrants acquired in the second and third quarter of 2020, respectively. The warrants acquired in the second quarter of 2021 had an exercise price of $ 2.00 per share. All of the warrants were exercisable immediately within five years from the issuance date of the warrants and included a cashless exercise option. We used the Black-Scholes-Merton pricing model to estimate the fair value of these warrants. On February 17, 2022, ISO entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $ 15.0 million. The note bore an annual interest rate of 0.59 % and matured and became payable on August 18, 2022 unless it was converted at a conversion price of $ 1.48 before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis’ financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at 59.9 % as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $ 64.5 million and $ 31.4 million, respectively. The remeasurement resulted in a $ 7.7 million loss in the first quarter of 2022 which was included in c hanges in fair values of equity and long-term investments, net on the unaudited condensed consolidated statement of income for the nine months ended September 30, 2022. We completed our acquisition of Entasis’ minority interest on July 11, 2022. No payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the “Replacement Warrants”) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity. We recognized the difference between the acquisition price and the carrying value of the acquired minority interest on July 11, 2022 in our additional paid-in capital. The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management’s best estimates and assumptions. After the acquisition in July 2022, we adjusted the purchase price allocation based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities. During the third quarter of 2022, we recorded measurement period adjustments of $ 2.3 million decrease in goodwill, primarily related to a decrease in estimated purchase price of $ 1.4 million, an increase in noncontrolling interests of $ 1.7 million, and an increase in intangible assets of $ 2.5 million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the three and nine months ended September 30, 2022 was not material. The Company has completed a preliminary valuation and expects to finalize it as soon as practical, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized. The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction: (In thousands) February 17, 2022 Cash and cash equivalents $ 23,070 Prepaid expenses 5,554 Other current assets 1,959 Property and equipment, net 185 Right-of-use assets 959 Goodwill 3,284 Intangible assets 107,500 Other assets 302 Total assets acquired $ 142,813 Accounts payable $ 1,583 Accrued personnel-related expenses 1,057 Other current liabilities 5,097 Deferred tax liabilities 360 Total liabilities assumed $ 8,097 Total assets acquired, net $ 134,716 The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis’ assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes . Refer to Note 7, “Goodwill and Intangible Assets” for more discussion on the intangible assets recognized as part of this acquisition. Our unaudited condensed consolidated net income for the three and nine months ended September 30, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition of $ 2.7 million and $ 13.6 million, respectively. La Jolla Pharmaceutical Company On August 22, 2022, ISO acquired La Jolla for a total consideration of $ 206.6 million. ISO acquired La Jolla at a price of $ 6.23 per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brings to Innoviva an established product portfolio, including GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs). The fair values assigned to assets acquired and liabilities assumed are based on management’s best estimates and assumptions as of August 22, 2022. We have completed a preliminary valuation and expect to finalize it as soon as practicable, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized. We incurred approximately $ 4.9 million in acquisition-related costs in connection with this acquisition and such amount is included in selling, general and administrative expenses for the three and nine months ended September 30, 2022. The following table summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition: (In thousands) August 22, 2022 Cash and cash equivalents $ 47,415 Short-term marketable securities 471 Accounts receivable 5,876 Inventory 73,900 Prepaid expenses 1,261 Other current assets 907 Property and equipment, net 13 Right-of-use assets 226 Goodwill 12,711 Intangible assets 152,500 Other assets 710 Total assets acquired $ 295,990 Accounts payable $ 1,237 Deferred revenue, current 2,849 Other accrued liabilities 11,062 Other long-term liabilities 74,283 Total liabilities assumed $ 89,431 Total assets acquired, net $ 206,559 The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla’s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes . Refer to Note 7, “Goodwill and Intangible Assets” for more discussion on the intangible assets recognized as part of this acquisition. Pro Forma Financial Information The following table presents certain unaudited pro-forma financial information for the three and nine months ended September 30, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2022, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis’ common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Revenue $ 72,830 $ 111,176 $ 292,077 $ 347,696 Net income $ 221,473 $ 45,109 $ 266,797 $ 183,252 Net income attributable to Innoviva stockholders $ 272,797 $ 19,892 $ 276,200 $ 129,803 |
Financial Instruments and Fair
Financial Instruments and Fair Value Measurements | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Financial Instruments and Fair Value Measurements | 6. Financial Instruments and Fair Value Measurements Equity Investment in Armata During the first quarter of 2020, Innoviva acquired 8,710,800 shares of common stock as well as warrants to purchase 8,710,800 additional shares of common stock of Armata Pharmaceuticals, Inc. (“Armata”) for approximately $ 25.0 million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections. During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire 6,153,847 shares of Armata common stock and warrants to purchase 6,153,847 additional shares of Armata common stock for approximately $ 20.0 million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than 49.5 % of the total number of shares of Armata’s common stock for voting on the matters related to election or removal of Armata’s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata’s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional 1,212,122 shares of Armata common stock for approximately $ 4.0 million. On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire 9,000,000 shares of Armata common stock and warrants to purchase 4,500,000 additional shares of common stock with an exercise price of $ 5.00 per share for $ 45.0 million. The investment closed in two tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than 49.5 % of the total number of shares of Armata’s common stock for voting on the matters related to election or removal of Armata’s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective da te and approval by the FDA of any of Armata’ s product candidates for marketing and commercial distribution. In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5 % of the outstanding shares of Armata ’s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata’ s board of directors, and for so long as the Company and ISO hold at least 8 %, but less than 12.5 %, of the outstanding shares of Armata ’s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata’ s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement. As of September 30, 2022 , three of the eight members of Armata’s board of directors are also members of the board of directors of Innoviva. As of September 30, 2022 and December 31, 2021, the Company and ISO owned approximately 69.4 % a nd 59.3 %, respectively, of Armata’s common stock. The investments in Armata provide Innoviva and ISO the ability to have significant influence, but not control over Armata’s operations. Armata’s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We account for both Armata’s common stock and warrants under the equity method using the fair value option. The fair value of Armata’s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $ 2.87 , $ 3.25 and $ 5.00 per share, respectively. All warrants are exercisable immediately within five years from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata’s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. As of September 30, 2022, the fair values of our holdings of Armata common stock and warrants were estimated at $ 105.8 million and $ 50.6 million, respectively. As of December 31, 2021 , the fair values of our holdings of Armata common stock and warrants were estimated at $ 88.1 million and $ 58.6 million, respectively. The total fair value of both financial instruments in the amount of $ 156.4 million and $ 146.7 million was recorded as equity and long-term investments on the unaudited condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022 , we recorded $ 11.7 million unrealized gain and $ 35.3 million unrealized loss, respect ively, as changes in fair values of equity and long-term investments, net on the unaudited condensed consolidated statements of income. During the three and nine months ended September 30, 2021, we recorded $ 11.6 million unrealized loss and $ 25.3 million unrealized gain , respectively, as changes in fair values of equity and long-term investments, net on the unaudited condensed consolidated statements of income. The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows: Income Statement Information Three Months Ended June 30, Nine Months Ended June 30, (In thousands) 2022 2021 2022 2021 Revenue $ 1,883 $ 1,168 $ 4,108 $ 2,738 Loss from operations $ ( 9,220 ) $ ( 6,196 ) $ ( 24,043 ) $ ( 18,084 ) Net loss $ ( 9,215 ) $ ( 6,194 ) $ ( 24,036 ) $ ( 18,313 ) Equity Investment in InCarda During the third quarter of 2020, TRC purchased 20,469,432 shares of Series C preferred stock and a warrant to purchase 5,117,358 additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (“InCarda”) (the “InCarda 2020 Warrant”) for $ 15.8 million, which included $ 0.8 million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythm TM (flecainide for inhalation), InCarda’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to Innoviva’s wholly-owned subsidiary, Innoviva TRC Holdings, LLC (“ITH”) all of TRC’s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda’s board of directors. As of September 30, 2022 , one of InCarda’s eight board members was designated by ITH. The InCarda 2020 Warrant is exercisable immediately with an exercise price of $ 0.7328 per share. In September 2021, TRC and InCarda entered into an amendment to extend the expiration date of the InCarda 2020 Warrant from October 6, 2021 to March 31, 2022. On March 9, 2022, TRC and InCarda entered into an amendment to further extend the expiration date of the InCarda 2020 Warrant from March 31, 2022 to March 31, 2023 . The InCarda 2020 Warrant is recorded at fair value and subject to remeasurement at each balance sheet date. On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the “InCarda Agreement”) with InCarda to acquire a convertible promissory note (the “InCarda Convertible Note”) and warrants (the “InCarda 2022 Warrant”) for $ 0.7 million. The InCarda Convertible Note bears an annual interest rate of 6 % and will convert into Series D preferred stock upon a qualified financing, non-qualified financing, or maturity conversion. A qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of at least $ 10.0 million (excluding the aggregate amount of any notes converted into equity securities pursuant to the conversion of notes or any other debt securities converted into equity securities) (the “Qualified Financing Amount”). A non-qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of less than the Qualified Financing Amount. The InCarda 2022 Warrant entitles TRC to purchase a number of shares of equity securities equal to 100 % of the principal amount of the InCarda Convertible Note divided by the number of shares issued in InCarda’s next equity financing, which is defined as the earliest to occur of specific financing events, including capital raises through public offerings. The InCarda 2022 Warrant expires on March 9, 2027. The InCarda Convertible Note and InCarda 2022 Warrant are measured at fair value. On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda’s Series D preferred stock financing by investing $ 2.3 million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning 4,093,886 shares of InCarda’s common stock, 37,350 shares of its Series A-1 preferred stock, 20,469,432 shares of its Series C preferred stock, 8,771,780 shares of its Series D-1 preferred stock, 3,369,802 shares of its Series D-2 preferred stock, a warrant to purchase 5,117,358 shares of its Series C preferred stock at $ 0.73 per share and a warrant to purchase 2,490,033 shares of its Series D-2 preferred stock at $ 0.26 per share. As of September 30, 2022, we held 8.9 % of InCarda equity ownership. A s of December 31, 2021, TR C held 13.0 % of InCarda equity ownership. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda’s operations. Based on our evaluation, we determined that InCarda is a VIE, but we ar e not the primary beneficiary of the VIE. We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda’s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model include an expected holding period of two years , a risk free interest rate of 3.2 %, a dividend yield of 0.0 % and an estimated volatility of 122.0 %. The estimated volatility is calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $ 9.0 million. There was no impairment or other change to the value of our investments in InCarda as of December 31, 2021. As of September 30, 2022, we recorde d $ 6.8 million in fair value of InCarda’s Series C preferred stock and $ 0.5 million in fair value of Series C warrants and Series D warrants (the “InCarda Preferred Stock Warrants”). As of September 30, 2022 , we recognized $ 3.2 million for InCarda’s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2021 , we recorded $ 0.4 million in fair value of InCarda’s 2020 Warrants. As of December 31, 2021 , we recognized $ 15.8 million for the investment in InCarda’s Series C preferred stock using the measurement alternative. During the three and nine months ended September 30, 2022, we recorded $ 0.2 million in net unrealized gain and $ 8.8 million in net unrealized loss, respectively, as changes in fair values of equity and long-term investments, net on the unaudited condensed consolidated statements of income . During the three and nine months ended September 30, 2021, we recorded $ 0.1 million unrealized gain and $ 0.6 million of unrealized loss , respectively, as changes in fair values of equity and long-term investments, net on the unaudited condensed consolidated statements of income. Equity Investment in ImaginAb During the first quarter of 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. to purchase 4,051,724 shares of ImaginAb Series C preferred stock for $ 4.7 million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb’s common stockholders to purchase 4,097,157 shares of ImaginAb common stock for $ 1.3 million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $ 0.4 million was incurred for investment due diligence costs and execution and recorded as part of the equity investment on the condensed consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC’s ownership interests and investments in ImaginAb. As of September 30, 2022 , one of ImaginAb’s five bo ard members was designated by ITH. As of September 30, 2022 , we held 11.5 % of ImaginAb equity ownership. As of December 31, 2021 , TRC held 14.5 % of ImaginAb equity ownership. Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb’s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. Because ImaginAb’s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb’s Series C preferred stock and common stock using the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. As of September 30, 2022 and December 31, 2021 , $ 6.4 million was recorded as equity and long-term investments on the unaudited condensed consolidated balance sheets and there was no change to the fair value of our investment. Convertible Promissory Note in Gate Neurosciences During the fourth quarter of 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate Neurosciences, Inc. (“Gate”) to acquire a convertible promissory note (the “Gate Convertible Note”) with a principal amount of $ 15.0 million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund its ongoing development and research. The Gate Convertible Note bears an annual interest rate of 8 % and will convert into shares of common stock of Gate upon a qualified event or into shares of shadow preferred stock of Gate (“Shadow Preferred”) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (“SPAC”). The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the “Capped Conversion Price”) and the qualified event price (the “Qualified Event Price”). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC’s debt investments in Gate. Our investment in Gate does not provide us with the ability to control or have significant influence over Gate’s operations. Based on our evaluation, we determined that Gate is a VIE, but we are not the primary beneficiary of the VIE. We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. ITH has the right to designate one board member to Gate’s board. As of September 30, 2022, one board member was designated by ITH to Gate’s board, which currently consists of three directors. As of September 30, 2022 and December 31, 2021, the fair value of the Gate Convertible Note was estimated at $ 15.4 million and $ 15.1 million, respectively, and recorded as equity and long-term investments on the unaudited condensed consolidated balance sheets. We rec orded $ 0.2 million and $ 0.3 million unrealized gain, respectively, as changes in fair values of equity and long-term investments, net on the unaudited condensed consolidated state ment of income for the three and nine months ended September 30, 2022. Equity Investment in Nanolive On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive SA (“Nanolive”) to purchase 18,750,000 shares of Nanolive Series C preferred stock for $ 9.8 million (equivalent to 9.0 million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therap y. $ 0.7 million was incurred fo r investment due diligence costs and execution and recorded as part of the equity and long-term investment on the condensed consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC’s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive’s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another majority common stockholder, to Nanolive’s board. As of September 30, 2022 , one of Innoviva designees is serving on Nanolive’s seven -member board. As of September 30, 2022, we held 15.5 % of Nanolive equity ownership. Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive’s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. Because Nanolive’s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive’s Series C preferred stock using the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. As of September 30, 2022, $ 10.6 million was recorded as equity and long-term investments on the unaudited condensed consolidated balance sheets and there was no change to the fair value of our investment. Fair Value Measurements Our equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. Estimated Fair Value Measurements as of September 30, 2022 Using: Quoted Price Significant Significant Identical Observable Unobservable Types of Instruments Assets Inputs Inputs (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 261,718 $ — $ — $ 261,718 Short-term marketable securities 282 — — 282 Investments held by ISP Fund LP (1) 236,624 — 53,163 289,787 Equity investment - Armata Common Stock 105,824 — — 105,824 Equity investment - Armata Warrants — 50,605 — 50,605 Equity investment - InCarda Series C Preferred Stock — — 6,809 6,809 Equity investment - InCarda Preferred Stock Warrants — — 501 501 Convertible debt investment - Gate Note — — 15,400 15,400 Total assets measured at estimated fair value $ 604,448 $ 50,605 $ 75,873 $ 730,926 Liabilities Debt 2023 Notes $ — $ 95,001 $ — $ 95,001 2025 Notes — 185,041 — 185,041 2028 Notes — 202,241 — 202,241 Total fair value of debt $ — $ 482,283 $ — $ 482,283 Contingent value rights — — 294 294 Total liabilities measured at estimated fair value $ — $ 482,283 $ 294 $ 482,577 (1) The investments held by ISP Fund LP, consisted of $ 246.0 million in equity investments, which included private placement positions and convertible notes of $ 53.2 million, $ 38.7 million in money market funds and $ 5.1 million in cash. Our total capital contribution of $ 300.0 million is subject to a 36-month lock-up period from the date of such capital contributions. Estimated Fair Value Measurements as of December 31, 2021 Using: Quoted Price in Active Significant Markets for Other Significant Identical Observable Unobservable Types of Instruments Assets Inputs Inputs (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 145,132 $ — $ — $ 145,132 Investments held by ISP Fund LP (1) 193,677 — 2,068 195,745 Equity investment - Armata Common Stock 88,101 — — 88,101 Equity investment - Armata Warrants — 58,595 — 58,595 Equity investment - Entasis Common Stock 62,794 — — 62,794 Equity investment - Entasis Warrants — 40,914 — 40,914 Equity investment - InCarda Warrants — — 411 411 Convertible debt investment - Gate Note — — 15,100 15,100 Total assets measured at estimated fair value $ 489,704 $ 99,509 $ 17,579 $ 606,792 Debt 2023 Notes $ — $ 261,769 $ — $ 261,769 2025 Notes — 234,498 — 234,498 Total fair value of debt $ — $ 496,267 $ — $ 496,267 (1) The investments held by ISP Fund LP, consisted of $ 192.2 million equity investments and $ 3.5 million money market funds, are subject to a 36 -month lock-up period from our initial contribution date, December 11, 2020. The fair values of our equity investments in Armata’s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values of the warrants of Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications. InCarda’s equity securities, the Gate Convertible Note, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. The fair values of our 2023 Notes, 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 9 Months Ended |
Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | 7. Goodwill and Intangible Assets Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of September 30, 2022 was $ 16.0 million . We have not recognized any impairment losses related to goodwill during the periods presented. Intangible assets with definite lives are amortized over their estimated useful lives. The carrying basis and accumulated amortization of recognized intangible assets as of September 30, 2022 were as follows: Useful Life Gross Accumulated Net Carrying (In thousands) (Years) Amount Amortization Amount Marketed products 8 - 10 $ 152,500 $ ( 1,511 ) $ 150,989 In-process research and development 72,100 — 72,100 Collaboration agreement 35,400 — 35,400 Total $ 260,000 $ ( 1,511 ) $ 258,489 Intangible assets recognized as a result of the acquisition of Entasis amounted to $ 107.5 million, which consist of Entasis’ in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $ 72.1 million and $ 35.4 million, respectively. The useful l ives of these intangible assets will be determined upon commercialization of the underlying product candidates; thus, no amortization expense of determinable assets was recognized during the period ended September 30, 2022. Intangible assets recognized as a result of the acquisition of La Jolla amounting to $ 152.5 million pertain to product rights and developed technologies on La Jolla’s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives. We recognized amortization expense of $ 1.5 million for the three and nine months ended September 30, 2022. Future amortization expense is expected to be $ 3.5 million for the remainder of 2022, $ 13.8 million for each of the years from 2023 to 2026 and $ 78.0 million thereafter. |
Balance Sheet Components
Balance Sheet Components | 9 Months Ended |
Sep. 30, 2022 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance Sheet Components | 8. Balance Sheet Components Inventory Inventory consisted of the following: September 30, (in thousands) 2022 Raw materials $ 5,757 Work-in-progress 54,126 Finished goods 10,924 Total inventory $ 70,807 As of September 30, 2022, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $ 64.1 million , which will be amortized and recognized as cost of products sold when sales occur in future periods. Amortization of fair value adjustments recorded as part of cost of products sold amounted to $ 2.7 million for the three and nine months ended September 30, 2022 . There was no inventory as of December 31, 2021. Other Accrued Liabilities Other accrued liabilities consisted of the following: September 30, December 31, (in thousands) 2022 2021 Accrued contract manufacturing expenses $ 5,319 $ — Accrued clinical expenses 1,062 — Accrued research expenses 692 — Accrued professional services 3,542 894 Current portion of lease liabilities 1,170 106 Accrued license fees and royalties 1,155 — Other 2,180 9 Total other accrued liabilities $ 15,120 $ 1,009 Other Long-term Liabilities Other long-term liabilities consisted of the following: September 30, (in thousands) 2022 Long-term portion of lease liabilities $ 2,703 Deferred royalty obligation 75,424 Contingent value rights liability 294 Total other long-term liabilities $ 78,421 There were no other long-term liabilities as of December 31, 2021. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-Based Compensation | 9. Stock-Based Compensation Stock- Based Compensation Expense The following table summarizes stock-based compensation expense, which included the expense associated with Entasis’ equity awards due to consolidation from February 17, 2022 to July 11, 2022 and the expense for Innoviva replacement restricted stock units in connection with the acquisition of Entasis on July 11, 2022, for the three and nine months ended September 30, 2022: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Selling, general and administrative $ 2,422 $ 542 $ 4,240 $ 1,463 Research and development 1,295 — 1,781 — Total $ 3,717 $ 542 $ 6,021 $ 1,463 Valuation Assumptions Black-Scholes-Merton assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows: Nine Months Ended September 30, 2022 2021 Risk-free interest rate 1.6 % - 3.03 % 1.07 % - 1.13 % Expected term (in years) 5.50 - 6.11 6.00 Volatility 38.8 % - 40.5 % 45.0 % Dividend yield — % — % Weighted-average estimated fair value of stock options granted $ 6.98 - $ 7.73 $ 5.61 There were no grants of stock options during the three months ended September 30, 2022 and 2021. |
Debt
Debt | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Debt | 10. Debt Our debt consisted of the following: September 30, December 31, (In thousands) 2022 2021 2023 Notes $ 96,204 $ 240,984 2025 Notes 192,500 192,500 2028 Notes 261,000 — Total debt 549,704 433,484 Less: Unamortized debt discount and issuance costs ( 9,894 ) ( 38,831 ) Total debt, net $ 539,810 $ 394,653 Less: Current portion of long-term debt, net 96,131 — Total long-term debt, net $ 443,679 $ 394,653 Convertible Subordinated Notes Due 2023 In January 2013, we completed an underwritten public offering of $ 287.5 million aggregate principal amount of our 2023 Notes, which will mature on January 15, 2023 . The financing raised proceeds, net of issuance costs, of approximately $ 281.2 million, less $ 36.8 million to purchase two privately negotiated capped call option transactions in connection with the issuance of the notes. The 2023 Notes bear interest at the rate of 2.125 % per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013. At the option of the holders, the 2023 Notes may be converted into fully paid and non-assessable shares of our common stock prior to the close of the business on the second business day immediately preceding the final maturity date. The initial conversion rate was 35.9903 shares per $1,000 principal amount of the 2023 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $ 27.79 per share. In the event of default or a fundamental change (as defined in the indenture governing the 2023 Notes), holders of the 2023 Notes may require us to repurchase all or a portion of their 2023 Notes at price equal to 100 % of the principal amount of the 2023 Notes, plus any accrued and unpaid interest. In connection with the offering of the 2023 Notes, we entered into two privately negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $ 27.79 per share for the underlying number of shares and a cap price of $ 38.00 per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $ 38.00 per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from zero , if the stock price was below $ 27.79 per share, to a maximum of 2,779,659 shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call. As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to 50.5818 shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents a conversion price of approximately $ 19.77 per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $ 19.77 and $ 27.04 , respectively. During 2016, we retired a portion of our 2023 Notes with a face value of $ 14.1 million and carrying value of $ 13.9 million by way of purchase in the open market. On March 7, 2022, we used $ 165.6 million from the sale of the 2028 Notes to repurchase 60 % of the 2023 Notes with a face value of $ 144.8 million. The carrying value of the repurchased 2023 Notes was $ 144.5 million. Accrued interest was $ 0.4 million and unamortized debt issuance costs were $ 0.3 million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $ 20.7 million in other expense, net in the unaudited condensed consolidated statement of operations. The repurchase reduced the outstanding principal balance to $ 96.2 million and unamortized debt issuance costs to $ 0.2 million. The annual effective interest rate of the 2023 Notes changed from 2.36 % to 2.37 %. On April 18, 2022, certain 2023 Notes holders converted their notes of $ 3.0 thousand into Innoviva’s common stock. The outstanding principal balance was reduced slightly to $ 96.2 million. Our outstanding 2023 Notes balances consisted of the following: September 30, December 31, (In thousands) 2022 2021 Principal $ 96,204 $ 240,984 Debt issuance costs, net ( 73 ) ( 620 ) Net carrying amount $ 96,131 $ 240,364 The following table sets forth total interest expense recognized related to the 2023 Notes for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Contractual interest expense $ 511 $ 1,280 $ 2,106 $ 3,840 Amortization of debt issuance costs 59 143 240 431 Total interest and amortization expense $ 570 $ 1,423 $ 2,346 $ 4,271 Convertible Senior Notes Due 2025 On August 7, 2017, we completed a private placement of $ 192.5 million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $ 17.5 million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of 2.5 % per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018. The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is 57.9240 shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $ 17.26 per share), representing a 30.0 % conversion premium over the last reported sale price of the Company’s common stock on August 1, 2017, which was $ 13.28 per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on August 15, 2025 , unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, as described below. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time. Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances: • after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than 130 % of the current conversion price of the 2025 Notes; • for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than 98 % of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and, • upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes. In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to 100 % of the principal amount of the 2025 Notes, plus any accrued and unpaid interest. Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The adoption of ASU 2020-06 had a material impact on the 2025 notes. Refer to Note 1, “Description of Operations and Summary of Significant Accounting Policies” for further information. Prior to the adoption of ASU 2020-06, we separately account for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (“equity component”) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $ 67.3 million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $ 5.4 million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $ 3.5 million and equity issuance costs of $ 1.9 million. Issuance costs attributable to the liability component were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was 8.87 %. Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was 2.88 %. Our outstanding 2025 Notes balances consisted of the following: September 30, December 31, (In thousands) 2022 2021 Principal $ 192,500 $ 192,500 Debt discount and issuance costs, net ( 2,092 ) ( 38,211 ) Net carrying amount $ 190,408 $ 154,289 Equity component, net $ — $ 65,361 The following table sets forth total interest expense recognized related to the 2025 Notes for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Contractual interest expense $ 1,203 $ 1,203 $ 3,609 $ 3,609 Amortization of debt issuance costs 174 166 517 487 Amortization of debt discount — 1,997 — 5,859 Total interest and amortization expense $ 1,377 $ 3,366 $ 4,126 $ 9,955 Convertible Senior Notes Due 2028 In March 2022, we completed a private placement of $ 261.0 million aggregate principal amount of our 2028 Notes, which will mature on March 15, 2028 . The proceeds include the 2028 Notes sold pursuant to the $ 45.0 million over-allotment option granted by us to the initial purchasers, of which $ 36.0 million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the sale of the $261.0 million aggregate principal amount of 2028 Notes were approximately $ 252.6 million after deducting the initial purchasers’ discounts and commissions and our estimated offering expenses. We used approximately $ 21.0 million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $ 165.6 million of the remaining net proceeds to repurchase $ 144.8 million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes. The 2028 Notes bear interest at an annual rate of 2.125 % that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022. The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was 38.1432 shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $ 26.22 per share. Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes. Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances: • after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than 130 % of the current conversion price of the 2028 Notes; • for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than 98 % of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and, • upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes. The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption. If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be 100 % of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date. The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately. In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $ 33.9850 per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap. The annual effective interest rate on the 2028 Notes is 2.70 %. Our outstanding 2028 Notes balance as of September 30, 2022 consisted of the following: (In thousands) September 30, 2022 Principal $ 261,000 Debt issuance costs, net ( 7,729 ) Net carrying amount $ 253,271 The following table sets forth total interest expense recognized related to the 2028 Notes from the date of issuance through September 30, 2022: Three Months Ended September 30, Date of Issuance through September 30, (In thousands) 2022 2022 Contractual interest expense $ 1,371 $ 3,127 Amortization of debt issuance costs 328 735 Total interest and amortization expense $ 1,699 $ 3,862 Debt Maturities The aggregate scheduled maturities of our convertible debt as of September 30, 2022 were as follows: (In thousands) September 30, 2022 Years ending December 31: Remainder of 2022 $ — 2023 96,204 2024 — 2025 192,500 2026 — Thereafter 261,000 Total $ 549,704 Deferred Royalty Obligation As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla’s royalty financing agreement (“La Jolla Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA ® until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is 14 %. Starting January 1, 2024, the maximum royalty rate may increase by an additional 4 %, if an agreed-upon, cumulative net product sales threshold has not been met. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $ 225.0 million. For the three months ended September 30, 2022 , we recognized interest expense, including amortization of the obligation discount of $ 1.5 million. The carrying value of the deferred royalty obligation as of September 30, 2022 was $ 79.9 million, net of unamortized obligation discount of $ 0.5 million. $ 75.4 million of the deferred royalty obligation, including the long-term portion of the accrued interest, was classified as a noncurrent liability and the remaining $ 4.5 million represented the short-term accrued interest. During the three months ended September 30, 2022 , we made royalty payments to HCR of $ 1.0 million. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of September 30, 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA ® . Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA ® , HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $ 125.0 million or $ 225.0 million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of September 30, 2022 , inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $ 11.6 million of aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA ® -related assets. HCR has no recourse against any asset other than GIAPREZA ® . Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of September 30, 2022 . We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the unaudited condensed consolidated statements of income. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. Commitments and Contingencies Operating Lease We have operating leases for our corporate headquarters, office spaces and laboratory facilities. The components of lease cost are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2022 Straight line operating lease costs $ 640 $ 1,101 Variable lease costs 35 110 Total lease costs $ 675 $ 1,211 Supplemental cash flow information related to leases are as follows: Nine Months Ended September 30, (In thousands) 2022 Cash paid for amounts included in the measurement of operating lease liabilities: $ 540 Operating lease right-of-use assets obtained in exchange for operating lease obligations 3,323 Right-of-use assets obtained through acquisitions 1,185 As of September 30, 2022 , our operating leases have weighted-average remaining term of approximately three years and the weighted average discount rate on our operating lease liabilities was 7.5 %. We have not presented the comparative information above as our operating lease in 2021 was not material. The following table summarizes our operating leases as presented in the unaudited condensed consolidated balance sheets: September 30, December 31, (In thousands) 2022 2021 Assets Right-of-use assets $ 3,679 $ 97 Liabilities Current portion of lease liabilities $ 1,170 $ 106 Long-term portion of lease liabilities 2,703 — Total lease liabilities $ 3,873 $ 106 Future minimum payments on our operating leases as of September 30, 2022 were as follows: (In thousands) September 30, 2022 Years ending December 31: Remainder of 2022 $ 250 2023 1,542 2024 1,269 2025 1,289 Total undiscounted lease payments 4,350 Less: imputed interest ( 477 ) Total operating lease liabilities $ 3,873 Legal Proceedings From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below. As previously disclosed in the Quarterly Report on Form 10-Q filed by La Jolla on August 15, 2022, on February 15, 2022, La Jolla received a paragraph IV notice of certification (the “Notice Letter”) from Gland Pharma Limited (“Gland”) advising that Gland had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA ® in the U.S. prior to the expiration of U.S. Patent No.s.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the “GIAPREZA ® Patents”), which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). The Notice Letter alleges that the GIAPREZA ® Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland’s ANDA. On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA ® Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland’s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA ® is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland’s ANDA any earlier than 7.5 years from the approval of the GIAPREZA ® NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA ® . Indemnification In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our unaudited condensed consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and have not accrued any material liabilities in the condensed consolidated financial statements as a result of these provisions. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes We recorded provisional income tax expe nse of $ 57.1 million and $ 63.1 million f or the three and nine months ended September 30, 2022, respectively, compared to provisional income tax expense of $ 20.5 million and $ 65.6 million for the three and nine months ended September 30, 2021, respectively. The Company’s effective income tax rate for the nine months ended September 30, 2022 wa s 18.3 %, com pared to 16.9 % for the same period in 2021. The income tax expense for the nine months ended September 30, 2022 and 2021 was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. Our effective income tax rate for the nine months ended September 30, 2022 was lower than the U.S. federal statutory income tax rate due primarily to a decrease in the fair value of our equity investments. |
Description of Operations and_2
Description of Operations and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and, in our opinion, include all adjustments, consisting of all normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive income and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022 or any other periods. The accompanying unaudited condensed consolidated financial statements include the accounts of Innoviva, our wholly-owned subsidiaries, and certain variable interest entities (“VIEs”) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income attributable to noncontrolling interest in our unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022, and as amended on March 17, 2022. Factors Affecting Comparability Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, “Consolidated Entities and Acquisitions”. • Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining minority interest in Entasis on July 11, 2022, • Sale of our 15 % ownership interest in Theravance Respiratory Company, LLC (“TRC”) on July 20, 2022, and • Acquisition of La Jolla on August 22, 2022. |
Factors Affecting Comparability | Factors Affecting Comparability Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, “Consolidated Entities and Acquisitions”. • Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining minority interest in Entasis on July 11, 2022, • Sale of our 15 % ownership interest in Theravance Respiratory Company, LLC (“TRC”) on July 20, 2022, and • Acquisition of La Jolla on August 22, 2022. |
Prior Period Immaterial Correction | Prior Period Immaterial Correction Subsequent to the issuance of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021, the Company identified that (i) purchases of equity investments managed by ISP Fund LP for $ 178.4 million, (ii) sales of equity investments managed by ISP Fund LP for $ 21.4 million, and (iii) purchase and sales of other investments managed by ISP Fund LP, net for $ 267.0 million were incorrectly included in the unaudited condensed consolidated statement of cash flows within the distribution of equity and long-term investments line item. The Company has corrected the presentation in the accompanying unaudited condensed consolidated statement of cash flows for the nine months ended September 30, 2021 from amounts previously reported to present such line items separately. The correction did not impact total cash flows from investing activities or the unaudited condensed consolidated balance sheet, statement of income, or statement of comprehensive income for the relevant period. Management assessed the correction on a quantitative and qualitative basis and determined that it is immaterial to the prior period unaudited condensed consolidated financial statements. |
Use of Management's Estimates | Use of Management’s Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. |
Concentrations of Credit Risk and of Significant Suppliers and Partner | Concentrations of Credit Risk and of Significant Suppliers and Partner Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits. We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (“API”) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products. Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts’ or investors’ expectations, due to a number of important factors. We also started recognizing revenue from product sales as a result of our acquisition of La Jolla. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. Three of our customers each comprise 10 % or more of our net product sales and they account for 32 %, 32 % and 29 %, respectively, of our net product sales from the time of La Jolla ’ s acquisition to September 30, 2022. These same customers account for 34 %, 23 % and 35 %, respectively, of our receivables from net product sales, which is included in “Accounts receivables, net” in our unaudited consolidated balance sheet as of September 30, 2022. Refer to Item 1A. “Risk Factors” disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and to the supplemental risk factors detailed in our Form 8-K filed on August 23, 2022 for further detail. |
Segment Reporting | Segment Reporting We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA ® and XERAVA ® . Our long-term assets are located within the United States. |
Variable Interest Entities | Variable Interest Entities We evaluate our ownership, contractual and other interest in entities to determine if they are a VIE. We evaluate whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluation, if we determine we are the primary beneficiary of a VIE, we consolidate the entity in our financial statements. |
Business Combination | Business Combination When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred. Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset’s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives. |
Cash and Cash Equivalents | Cash and Cash Equivalents We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value. |
Accounts Receivable, Net | Accounts Receivable, Net Accounts receivable, net are recorded net of estimates for prompt-pay discounts, chargebacks, returns, rebates, and administrative fees. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. |
Inventory | Inventory Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales . |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite lives are subject to impairment testing at least annually or more frequently if indicators for potential impairment exist. Intangible assets with definite lives are amortized on a straight-line basis over the remaining useful life of the intangible asset. These assets are tested for impairment whenever events or changes in circumstances indicate that an asset’s carrying amount may not be recoverable. Significant judgments are involved in determining if an indicator of impairment has occurred. |
Operating Leases | Operating Leases We account for our leases under ASC 842, Leases . Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term. |
Equity and Long-Term Investments | Equity and Long-Term Investments We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our unaudited condensed consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships. We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity and long-term investments, net within the unaudited condensed consolidated statements of income. If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, Investments - Equity Securities . This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which prevents us from having control and access to the contributions and related investments. These investments are classified as long-term investments on the unaudited condensed consolidated balance sheets. |
Revenue Recognition | Revenue Recognition Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied. Royalty Revenue from Collaboration Arrangement We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK. Revenue from Product Sales Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include: • Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers. • Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers. • Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. • Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. • Administrative Fees: We pay administrative fees to GPOs for services and access to data. Additionally, we pay an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers. We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly. |
Research and Development Costs | Research and Development Costs Research and development costs are expensed in the period that services are rendered or goods are received. Research and development costs consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities. |
Interest Expense on Deferred Royalty Obligation | Interest Expense on Deferred Royalty Obligation Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA ® . Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 6, “Financial Instruments and Fair Value Measurements” for more information. |
Accounting Pronouncement Adopted by the Company | Accounting Pronouncement Adopted by the Company In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (“EPS”) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $ 37.2 million, a reduction to additional paid-in capital of $ 65.4 million, an increase to the balance of the notes by an aggregate amount of $ 35.6 million, and an increase to deferred tax assets of $ 7.4 million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 10, “Debt” for more information. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers . During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our unaudited, condensed consolidated financial statements. |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of computation of basic and diluted net income per share | The following table shows the computation of basic and diluted net income per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands except per share data) 2022 2021 2022 2021 Numerator: Net income attributable to Innoviva stockholders, basic $ 265,523 $ 72,438 $ 282,235 $ 255,509 Add: interest expense on 2023 Notes 412 1,186 2,003 3,553 Add: interest expense on 2025 Notes 994 — 3,533 — Add: interest expense on 2028 Notes 1,769 — 3,862 — Net income attributable to Innoviva stockholders, diluted $ 268,698 $ 73,624 $ 291,633 $ 259,062 Denominator: Weighted-average shares used to compute basic net income 69,731 69,458 69,640 86,298 Dilutive effect of 2023 Notes 4,866 12,189 6,629 12,189 Dilutive effect of 2025 Notes 11,150 — 11,150 — Dilutive effect of 2028 Notes 9,955 — 7,559 — Dilutive effect of options and awards granted under equity 128 52 94 49 Weighted-average shares used to compute diluted net income 95,830 81,699 95,072 98,536 Net income per share attributable to Innoviva stockholders Basic $ 3.81 $ 1.04 $ 4.05 $ 2.96 Diluted $ 2.80 $ 0.90 $ 3.07 $ 2.63 |
Schedule of anti-dilutive securities | The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti-dilutive for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Outstanding options and awards granted under equity incentive 705 891 577 1,048 Outstanding stock warrant 526 — 177 — Total 1,231 891 754 1,048 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of net revenue from collaborative arrangements | Net revenue recognized under our GSK Agreements was as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Royalties $ 55,663 $ 54,092 $ 170,753 $ 176,398 Royalties 9,943 11,641 28,015 34,101 Royalties — 35,585 72,029 84,055 Total royalties from a related party 65,606 101,318 270,797 294,554 Less: amortization of capitalized fees ( 3,456 ) ( 3,456 ) ( 10,368 ) ( 10,368 ) Royalty revenue from GSK $ 62,150 $ 97,862 $ 260,429 $ 284,186 Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. |
Consolidated Entities and Acq_2
Consolidated Entities and Acquisitions (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Consolidated Entities | |
Pro Forma Information | The following table presents certain unaudited pro-forma financial information for the three and nine months ended September 30, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2022, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis’ common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Revenue $ 72,830 $ 111,176 $ 292,077 $ 347,696 Net income $ 221,473 $ 45,109 $ 266,797 $ 183,252 Net income attributable to Innoviva stockholders $ 272,797 $ 19,892 $ 276,200 $ 129,803 |
Theravance Respiratory Company, LLC | |
Consolidated Entities | |
Schedule of Balance Sheets and Income Statements of VIE | The summarized financial information of TRC as of December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows: Balance sheet December 31, (In thousands) 2021 Assets Cash and cash equivalents $ 50,713 Receivables from collaboration arrangement 42,492 Prepaid expenses and other current assets 71 Equity and long-term investments 37,695 Total assets $ 130,971 Liabilities and LLC Members’ Equity Current liabilities $ 252 LLC members’ equity 130,719 Total liabilities and LLC members’ equity $ 130,971 Income statements Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 (1) 2021 2022 (2) 2021 Royalty revenue from a related party $ — $ 35,585 $ 72,029 $ 84,055 Operating expenses ( 5 ) 194 332 3,811 Income from operations 5 35,391 71,697 80,244 Other income, net — — 10 — Realized loss ( 39,386 ) — ( 39,386 ) — Income tax expense, net — — 1 — Changes in fair values of equity and long-term — 148 ( 8,884 ) ( 589 ) Net income (loss) $ ( 39,381 ) $ 35,539 $ 23,438 $ 79,655 (1) Three months ended September 30, 2022 represents the period from July 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. (2) Nine months ended September 30, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. |
Entasis Therapeutics Holdings Inc | |
Consolidated Entities | |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction: (In thousands) February 17, 2022 Cash and cash equivalents $ 23,070 Prepaid expenses 5,554 Other current assets 1,959 Property and equipment, net 185 Right-of-use assets 959 Goodwill 3,284 Intangible assets 107,500 Other assets 302 Total assets acquired $ 142,813 Accounts payable $ 1,583 Accrued personnel-related expenses 1,057 Other current liabilities 5,097 Deferred tax liabilities 360 Total liabilities assumed $ 8,097 Total assets acquired, net $ 134,716 |
La Jolla Pharmaceutical Company | |
Consolidated Entities | |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition: (In thousands) August 22, 2022 Cash and cash equivalents $ 47,415 Short-term marketable securities 471 Accounts receivable 5,876 Inventory 73,900 Prepaid expenses 1,261 Other current assets 907 Property and equipment, net 13 Right-of-use assets 226 Goodwill 12,711 Intangible assets 152,500 Other assets 710 Total assets acquired $ 295,990 Accounts payable $ 1,237 Deferred revenue, current 2,849 Other accrued liabilities 11,062 Other long-term liabilities 74,283 Total liabilities assumed $ 89,431 Total assets acquired, net $ 206,559 The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla’s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes . Refer to Note 7, “Goodwill and Intangible Assets” for more discussion on the intangible assets recognized as part of this acquisition. Pro Forma Financial Information |
Financial Instruments and Fai_2
Financial Instruments and Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis | Our equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. Estimated Fair Value Measurements as of September 30, 2022 Using: Quoted Price Significant Significant Identical Observable Unobservable Types of Instruments Assets Inputs Inputs (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 261,718 $ — $ — $ 261,718 Short-term marketable securities 282 — — 282 Investments held by ISP Fund LP (1) 236,624 — 53,163 289,787 Equity investment - Armata Common Stock 105,824 — — 105,824 Equity investment - Armata Warrants — 50,605 — 50,605 Equity investment - InCarda Series C Preferred Stock — — 6,809 6,809 Equity investment - InCarda Preferred Stock Warrants — — 501 501 Convertible debt investment - Gate Note — — 15,400 15,400 Total assets measured at estimated fair value $ 604,448 $ 50,605 $ 75,873 $ 730,926 Liabilities Debt 2023 Notes $ — $ 95,001 $ — $ 95,001 2025 Notes — 185,041 — 185,041 2028 Notes — 202,241 — 202,241 Total fair value of debt $ — $ 482,283 $ — $ 482,283 Contingent value rights — — 294 294 Total liabilities measured at estimated fair value $ — $ 482,283 $ 294 $ 482,577 (1) The investments held by ISP Fund LP, consisted of $ 246.0 million in equity investments, which included private placement positions and convertible notes of $ 53.2 million, $ 38.7 million in money market funds and $ 5.1 million in cash. Our total capital contribution of $ 300.0 million is subject to a 36-month lock-up period from the date of such capital contributions. Estimated Fair Value Measurements as of December 31, 2021 Using: Quoted Price in Active Significant Markets for Other Significant Identical Observable Unobservable Types of Instruments Assets Inputs Inputs (In thousands) Level 1 Level 2 Level 3 Total Assets Money market funds $ 145,132 $ — $ — $ 145,132 Investments held by ISP Fund LP (1) 193,677 — 2,068 195,745 Equity investment - Armata Common Stock 88,101 — — 88,101 Equity investment - Armata Warrants — 58,595 — 58,595 Equity investment - Entasis Common Stock 62,794 — — 62,794 Equity investment - Entasis Warrants — 40,914 — 40,914 Equity investment - InCarda Warrants — — 411 411 Convertible debt investment - Gate Note — — 15,100 15,100 Total assets measured at estimated fair value $ 489,704 $ 99,509 $ 17,579 $ 606,792 Debt 2023 Notes $ — $ 261,769 $ — $ 261,769 2025 Notes — 234,498 — 234,498 Total fair value of debt $ — $ 496,267 $ — $ 496,267 (1) The investments held by ISP Fund LP, consisted of $ 192.2 million equity investments and $ 3.5 million money market funds, are subject to a 36 -month lock-up period from our initial contribution date, December 11, 2020. |
Armata | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Schedule of Income Statement Information | The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows: Income Statement Information Three Months Ended June 30, Nine Months Ended June 30, (In thousands) 2022 2021 2022 2021 Revenue $ 1,883 $ 1,168 $ 4,108 $ 2,738 Loss from operations $ ( 9,220 ) $ ( 6,196 ) $ ( 24,043 ) $ ( 18,084 ) Net loss $ ( 9,215 ) $ ( 6,194 ) $ ( 24,036 ) $ ( 18,313 ) |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Accumulated Amortization of Recognized Intangible Assets | The carrying basis and accumulated amortization of recognized intangible assets as of September 30, 2022 were as follows: Useful Life Gross Accumulated Net Carrying (In thousands) (Years) Amount Amortization Amount Marketed products 8 - 10 $ 152,500 $ ( 1,511 ) $ 150,989 In-process research and development 72,100 — 72,100 Collaboration agreement 35,400 — 35,400 Total $ 260,000 $ ( 1,511 ) $ 258,489 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventory | Inventory consisted of the following: September 30, (in thousands) 2022 Raw materials $ 5,757 Work-in-progress 54,126 Finished goods 10,924 Total inventory $ 70,807 |
Schedule Of Other Accrued Liabilities | Other accrued liabilities consisted of the following: September 30, December 31, (in thousands) 2022 2021 Accrued contract manufacturing expenses $ 5,319 $ — Accrued clinical expenses 1,062 — Accrued research expenses 692 — Accrued professional services 3,542 894 Current portion of lease liabilities 1,170 106 Accrued license fees and royalties 1,155 — Other 2,180 9 Total other accrued liabilities $ 15,120 $ 1,009 |
Schedule of Other Long-term Liabilities | Other long-term liabilities consisted of the following: September 30, (in thousands) 2022 Long-term portion of lease liabilities $ 2,703 Deferred royalty obligation 75,424 Contingent value rights liability 294 Total other long-term liabilities $ 78,421 There were no other long-term liabilities as of December 31, 2021. |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of stock-based compensation expense | The following table summarizes stock-based compensation expense, which included the expense associated with Entasis’ equity awards due to consolidation from February 17, 2022 to July 11, 2022 and the expense for Innoviva replacement restricted stock units in connection with the acquisition of Entasis on July 11, 2022, for the three and nine months ended September 30, 2022: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Selling, general and administrative $ 2,422 $ 542 $ 4,240 $ 1,463 Research and development 1,295 — 1,781 — Total $ 3,717 $ 542 $ 6,021 $ 1,463 |
Summary of weighted-average assumptions used to calculate estimated value of stock options | Black-Scholes-Merton assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows: Nine Months Ended September 30, 2022 2021 Risk-free interest rate 1.6 % - 3.03 % 1.07 % - 1.13 % Expected term (in years) 5.50 - 6.11 6.00 Volatility 38.8 % - 40.5 % 45.0 % Dividend yield — % — % Weighted-average estimated fair value of stock options granted $ 6.98 - $ 7.73 $ 5.61 There were no grants of stock options during the three months ended September 30, 2022 and 2021. |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt | |
Schedule of debt | Our debt consisted of the following: September 30, December 31, (In thousands) 2022 2021 2023 Notes $ 96,204 $ 240,984 2025 Notes 192,500 192,500 2028 Notes 261,000 — Total debt 549,704 433,484 Less: Unamortized debt discount and issuance costs ( 9,894 ) ( 38,831 ) Total debt, net $ 539,810 $ 394,653 Less: Current portion of long-term debt, net 96,131 — Total long-term debt, net $ 443,679 $ 394,653 |
Aggregate scheduled maturities of convertible debt | The aggregate scheduled maturities of our convertible debt as of September 30, 2022 were as follows: (In thousands) September 30, 2022 Years ending December 31: Remainder of 2022 $ — 2023 96,204 2024 — 2025 192,500 2026 — Thereafter 261,000 Total $ 549,704 |
2023 Notes | |
Debt | |
Summary of liability and equity components of convertible notes | Our outstanding 2023 Notes balances consisted of the following: September 30, December 31, (In thousands) 2022 2021 Principal $ 96,204 $ 240,984 Debt issuance costs, net ( 73 ) ( 620 ) Net carrying amount $ 96,131 $ 240,364 |
Schedule of components of interest expense | The following table sets forth total interest expense recognized related to the 2023 Notes for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Contractual interest expense $ 511 $ 1,280 $ 2,106 $ 3,840 Amortization of debt issuance costs 59 143 240 431 Total interest and amortization expense $ 570 $ 1,423 $ 2,346 $ 4,271 |
2025 Notes | |
Debt | |
Summary of liability and equity components of convertible notes | Our outstanding 2025 Notes balances consisted of the following: September 30, December 31, (In thousands) 2022 2021 Principal $ 192,500 $ 192,500 Debt discount and issuance costs, net ( 2,092 ) ( 38,211 ) Net carrying amount $ 190,408 $ 154,289 Equity component, net $ — $ 65,361 |
Schedule of components of interest expense | The following table sets forth total interest expense recognized related to the 2025 Notes for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Contractual interest expense $ 1,203 $ 1,203 $ 3,609 $ 3,609 Amortization of debt issuance costs 174 166 517 487 Amortization of debt discount — 1,997 — 5,859 Total interest and amortization expense $ 1,377 $ 3,366 $ 4,126 $ 9,955 |
2028 Notes | |
Debt | |
Summary of liability and equity components of convertible notes | Our outstanding 2028 Notes balance as of September 30, 2022 consisted of the following: (In thousands) September 30, 2022 Principal $ 261,000 Debt issuance costs, net ( 7,729 ) Net carrying amount $ 253,271 |
Schedule of components of interest expense | The following table sets forth total interest expense recognized related to the 2028 Notes from the date of issuance through September 30, 2022: Three Months Ended September 30, Date of Issuance through September 30, (In thousands) 2022 2022 Contractual interest expense $ 1,371 $ 3,127 Amortization of debt issuance costs 328 735 Total interest and amortization expense $ 1,699 $ 3,862 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Components of Lease Cost | The components of lease cost are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2022 Straight line operating lease costs $ 640 $ 1,101 Variable lease costs 35 110 Total lease costs $ 675 $ 1,211 |
Schedule of Supplemental Cash Flow Information Related to Leases | Supplemental cash flow information related to leases are as follows: Nine Months Ended September 30, (In thousands) 2022 Cash paid for amounts included in the measurement of operating lease liabilities: $ 540 Operating lease right-of-use assets obtained in exchange for operating lease obligations 3,323 Right-of-use assets obtained through acquisitions 1,185 |
Schedule of Operating Lease Information Presented In Balance Sheet | The following table summarizes our operating leases as presented in the unaudited condensed consolidated balance sheets: September 30, December 31, (In thousands) 2022 2021 Assets Right-of-use assets $ 3,679 $ 97 Liabilities Current portion of lease liabilities $ 1,170 $ 106 Long-term portion of lease liabilities 2,703 — Total lease liabilities $ 3,873 $ 106 |
Schedule of Future Minimum Lease Payments | Future minimum payments on our operating leases as of September 30, 2022 were as follows: (In thousands) September 30, 2022 Years ending December 31: Remainder of 2022 $ 250 2023 1,542 2024 1,269 2025 1,289 Total undiscounted lease payments 4,350 Less: imputed interest ( 477 ) Total operating lease liabilities $ 3,873 |
Description of Operations and_3
Description of Operations and Summary of Significant Accounting Policies (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) Customer | Sep. 30, 2021 USD ($) | Jul. 20, 2022 | |
Description of Operations and Summary of Significant Accounting Policies | ||||
Decrease to accumulated deficit | $ 37,200 | |||
Reduction to Additional Paid in Capital | 65,400 | |||
Purchases of equity investments managed by ISP Fund LP | (92,951) | $ (178,445) | ||
Sales of equity investments managed by ISP Fund LP | 24,281 | 21,426 | ||
Purchase and sales of other investments managed by ISP Fund LP, net | (41,330) | 267,019 | ||
Increase in Deferred Tax Assets | $ 7,400 | |||
Number of customers | Customer | 3 | |||
Theravance Respiratory Company, LLC | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Equity method investment ownership percentage | 15% | |||
Customer Concentration Risk | Net Product Sales | La Jolla | Customer One | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 32% | |||
Customer Concentration Risk | Net Product Sales | La Jolla | Customer Two | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 32% | |||
Customer Concentration Risk | Net Product Sales | La Jolla | Customer Three | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 29% | |||
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer One | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 34% | |||
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer Two | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 23% | |||
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer Three | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 35% | |||
Prior Period Immaterial Correction | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Purchases of equity investments managed by ISP Fund LP | $ (178,400) | (178,400) | ||
Sales of equity investments managed by ISP Fund LP | 21,400 | 21,400 | ||
Purchase and sales of other investments managed by ISP Fund LP, net | $ 267,000 | $ 267,000 | ||
2025 Notes | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Increase in convertible notes | $ 35,600 | |||
Minimum | Customer Concentration Risk | Net Product Sales | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Concentration Risk, Percentage | 10% | |||
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Royalty rate for first level of annual global net sales (as a percent) | 15% | |||
Annual global sales level used to determine royalty rate | $ 3,000,000 | |||
Royalty rate for sales above first level of annual global net sales (as a percent) | 5% | |||
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Royalty rate for combination products (as a percent) | 6.50% | |||
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum | ||||
Description of Operations and Summary of Significant Accounting Policies | ||||
Royalty rate for combination products (as a percent) | 10% |
Net Income Per Share (Details)
Net Income Per Share (Details) - 2025 Notes - Convertible senior notes - $ / shares | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Aug. 07, 2017 | |
Debt Instrument [Line Items] | |||||
Dilutive effect of the assumed conversion premium | 0 | 0 | |||
Dilutive EPS of note | $ 0.37 | $ 0.41 | |||
Common Stock [Member] | |||||
Debt Instrument [Line Items] | |||||
Conversion price (dollars per share) | $ 17.26 | $ 17.26 | $ 17.26 |
Net Income Per Share - Basic an
Net Income Per Share - Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Numerator: | ||||
Net income attributable to Innoviva stockholders, basic | $ 265,523 | $ 72,438 | $ 282,235 | $ 255,509 |
Net income attributable to Innoviva stockholders, diluted | $ 268,698 | $ 73,624 | $ 291,633 | $ 259,062 |
Denominator: | ||||
Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders | 69,731 | 69,458 | 69,640 | 86,298 |
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan | 128 | 52 | 94 | 49 |
Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders | 95,830 | 81,699 | 95,072 | 98,536 |
Net income per share attributable to Innoviva stockholders | ||||
Basic net income per share | $ 3.81 | $ 1.04 | $ 4.05 | $ 2.96 |
Diluted net income per share | $ 2.80 | $ 0.90 | $ 3.07 | $ 2.63 |
2023 Notes | ||||
Numerator: | ||||
Add: interest expense on Notes | $ 412 | $ 1,186 | $ 2,003 | $ 3,553 |
Denominator: | ||||
Dilutive effect | 4,866 | 12,189 | 6,629 | 12,189 |
2025 Notes | ||||
Numerator: | ||||
Add: interest expense on Notes | $ 994 | $ 0 | $ 3,533 | $ 0 |
Denominator: | ||||
Dilutive effect | 11,150 | 0 | 11,150 | 0 |
2028 Notes | ||||
Numerator: | ||||
Add: interest expense on Notes | $ 1,769 | $ 0 | $ 3,862 | $ 0 |
Denominator: | ||||
Dilutive effect | 9,955 | 0 | 7,559 | 0 |
Net Income Per Share - Anti-Dil
Net Income Per Share - Anti-Dilutive Securities (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Anti-Dilutive Securities | ||||
Anti-dilutive securities (in shares) | 1,231 | 891 | 754 | 1,048 |
Equity incentive plans and ESPP | ||||
Anti-Dilutive Securities | ||||
Anti-dilutive securities (in shares) | 705 | 891 | 577 | 1,048 |
Outstanding Stock Warrant | ||||
Anti-Dilutive Securities | ||||
Anti-dilutive securities (in shares) | 526 | 0 | 177 | 0 |
Revenue Recognition - Schedule
Revenue Recognition - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue Recognition and Collaboration Arrangements | ||||
Net revenue | $ 67,257 | $ 97,862 | $ 265,536 | $ 284,186 |
Royalty revenue from a related party | ||||
Revenue Recognition and Collaboration Arrangements | ||||
Net revenue | 62,150 | 97,862 | 260,429 | 284,186 |
GSK | Royalty revenue from a related party | ||||
Revenue Recognition and Collaboration Arrangements | ||||
Royalties | 65,606 | 101,318 | 270,797 | 294,554 |
Less: amortization of capitalized fees paid to a related party | (3,456) | (3,456) | (10,368) | (10,368) |
Net revenue | 62,150 | 97,862 | 260,429 | 284,186 |
GSK | RELVAR/BREO | ||||
Revenue Recognition and Collaboration Arrangements | ||||
Royalties | 55,663 | 54,092 | 170,753 | 176,398 |
GSK | ANORO | ||||
Revenue Recognition and Collaboration Arrangements | ||||
Royalties | 9,943 | 11,641 | 28,015 | 34,101 |
GSK | TRELEGY | ||||
Revenue Recognition and Collaboration Arrangements | ||||
Royalties | $ 0 | $ 35,585 | $ 72,029 | $ 84,055 |
Revenue Recognition (Details)
Revenue Recognition (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Jul. 13, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Disaggregation of Revenue [Line Items] | |||||
Net revenue | $ 67,257 | $ 97,862 | $ 265,536 | $ 284,186 | |
GIAPREZA [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Net revenue | 3,800 | 3,800 | |||
XERAVA [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Net revenue | 1,300 | 1,300 | |||
GSK | |||||
Disaggregation of Revenue [Line Items] | |||||
Percentage of royalty payments not entitled to receive | 15% | ||||
La Jolla [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Net revenue | $ 5,100 | $ 5,100 |
License and Collaboration Arr_2
License and Collaboration Arrangements (Additional Information) (Details) $ in Millions | 3 Months Ended | 9 Months Ended |
Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | |
Zai Lab | Research and Development Support | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Revenues | $ 0 | |
Future potential milestone payment receivable | 91 | $ 91 |
PAION AG | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Future potential milestone payment receivable | 109.5 | 109.5 |
Everest Medicines Limited | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Additional regulatory milestone payments receivable | 8 | 8 |
Sales milestone payments receivable | $ 20 | $ 20 |
Royalties payable period after first commercial sale of product | 10 years | |
Everest Medicines Limited | Commercial Supply Agreement | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Percentage of reimbursed for direct and certain indirect manufacturing costs | 110% | |
Deferred revenue | $ 2.8 | $ 2.8 |
George Washington University | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Percentage of royalty payable on net sales | 6% | |
Percentage of royalty on payments received from sublicensees | 15% | |
Harvard University | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Percentage of royalty payable on net sales | 5% | |
Percentage of royalty on payments received from sublicensees | 20% | |
Clinical development and regulatory milestones amount payable | $ 15.1 | |
Percentage of minimum royalty rate | 4.50% | |
Percentage of maximum royalty based on achievement of annual net product sales thresholds | 7.50% | |
Paratek Pharmaceuticals, Inc. | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Percentage of royalty payable on net sales | 2.25% | |
Claim expiration | 2023-10 |
Consolidated Entities and Acq_3
Consolidated Entities and Acquisitions - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||
Jul. 20, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |||
Assets | ||||||||||||
Cash and cash equivalents | $ 300,789 | $ 135,115 | $ 300,789 | $ 135,115 | $ 201,525 | |||||||
Receivables from collaboration arrangement | 65,606 | 65,606 | 110,711 | |||||||||
Prepaid expenses | 7,932 | 7,932 | 1,367 | |||||||||
Equity and long-term investments | 489,111 | 489,111 | 483,845 | |||||||||
Total assets | 1,327,712 | 1,327,712 | 926,395 | |||||||||
Liabilities and LLC Members' Equity | ||||||||||||
Current liabilities | 163,884 | 163,884 | 5,807 | |||||||||
Total liabilities and stockholders' equity | 1,327,712 | 1,327,712 | $ 926,395 | |||||||||
Income statements | ||||||||||||
Total revenue | 67,257 | 97,862 | 265,536 | 284,186 | ||||||||
Operating expenses | (219,167) | (25,315) | (86,101) | (104,601) | ||||||||
Other expense (income), net | 28 | (652) | (750) | (2,036) | ||||||||
Income tax expense net | 57,077 | 20,531 | 63,061 | 65,600 | ||||||||
Changes in fair values of equity and long-term investments | 130 | 33,613 | (67,881) | 133,973 | ||||||||
Net income (loss) | 229,347 | $ 21,371 | $ 37,858 | 102,646 | $ 110,846 | $ 109,695 | 288,576 | 323,187 | ||||
Royalty revenue from a related party | ||||||||||||
Income statements | ||||||||||||
Total revenue | 62,150 | 97,862 | 260,429 | 284,186 | ||||||||
Theravance Respiratory Company, LLC | ||||||||||||
CONSOLIDATED ENTITIES | ||||||||||||
Ownership interest in LLC | 15% | |||||||||||
Proceeds from sale of economic interest under Equity Purchase Agreement | $ 277,500 | |||||||||||
Contingent sales based milestone payment | 50,000 | |||||||||||
Cash distribution | 4,400 | |||||||||||
Total carrying value of investments | $ 39,400 | |||||||||||
Assets | ||||||||||||
Cash and cash equivalents | $ 50,713 | |||||||||||
Receivables from collaboration arrangement | 42,492 | |||||||||||
Prepaid expenses | 71 | |||||||||||
Equity and long-term investments | 37,695 | |||||||||||
Total assets | 130,971 | |||||||||||
Liabilities and LLC Members' Equity | ||||||||||||
Current liabilities | 252 | |||||||||||
LLC members' equity | 130,719 | |||||||||||
Total liabilities and stockholders' equity | $ 130,971 | |||||||||||
Income statements | ||||||||||||
Operating expenses | (5) | [1] | 194 | 332 | [2] | 3,811 | ||||||
Income from operations | 5 | [1] | 35,391 | 71,697 | [2] | 80,244 | ||||||
Other expense (income), net | 0 | [1] | 0 | 10 | [2] | 0 | ||||||
Realized loss | (39,386) | [1] | 0 | (39,386) | [2] | 0 | ||||||
Income tax expense net | 0 | [1] | 0 | 1 | [2] | 0 | ||||||
Changes in fair values of equity and long-term investments | 0 | [1] | 148 | (8,884) | [2] | (589) | ||||||
Net income (loss) | (39,381) | [1] | 35,539 | 23,438 | [2] | 79,655 | ||||||
Theravance Respiratory Company, LLC | Royalty revenue from a related party | ||||||||||||
Income statements | ||||||||||||
Total revenue | $ 0 | [1] | $ 35,585 | $ 72,029 | [2] | $ 84,055 | ||||||
[1] Three months ended September 30, 2022 represents the period from July 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. Nine months ended September 30, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC. |
Consolidated Entities and Acq_4
Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||||
Jul. 11, 2022 USD ($) | Feb. 17, 2022 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) $ / shares shares | Sep. 30, 2020 USD ($) $ / shares shares | Jun. 30, 2020 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) Director | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Payments to acquire equity securities | $ 20,000 | |||||||||
Total debt | $ 549,704 | $ 549,704 | $ 433,484 | |||||||
Remeasurement loss | 7,700 | |||||||||
Net loss attributable to Innoviva stockholders | 265,523 | $ 72,438 | $ 282,235 | $ 255,509 | ||||||
Entasis Therapeutics Holdings Inc | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 14,000,000 | |||||||||
Number of investee's board members which may be designated by the Company | Director | 2 | |||||||||
Payment towards convertible promissory note | $ 0 | |||||||||
Net loss attributable to Innoviva stockholders | 2,700 | $ 13,600 | ||||||||
Measurement period adjustments for change in value of goodwill | (2,300) | |||||||||
Measurement period adjustments for change in estimated purchase price | (1,400) | |||||||||
Measurement period adjustments for change in value of noncontrolling interests | 1,700 | |||||||||
Measurement period adjustments for change in value of intangible assets | $ 2,500 | |||||||||
Entasis Therapeutics Holdings Inc | Consolidated Investees [Member] | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Equity method investment ownership percentage | 59.90% | |||||||||
Entasis Therapeutics Holdings Inc | Securities Purchase Agreement | Convertible Promissory Note | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Total debt | $ 15,000 | |||||||||
Debt instrument maturity date | Aug. 18, 2022 | |||||||||
Debt Instrument, annual interest rate | 0.59% | |||||||||
Conversion price (dollars per share) | $ / shares | $ 1.48 | |||||||||
Entasis Therapeutics Holdings Inc | Common stock | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 4,672,897 | |||||||||
Fair value of equity securities | $ 64,500 | |||||||||
Entasis Therapeutics Holdings Inc | Common stock | Innoviva Strategic Opportunities, LLC | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 10,000,000 | |||||||||
Entasis Therapeutics Holdings Inc | Warrants | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Number of warrants purchased under the securities purchase agreement | shares | 4,672,897 | 14,000,000 | ||||||||
Fair value of equity securities | $ 31,400 | |||||||||
Entasis Therapeutics Holdings Inc | Warrants | Innoviva Strategic Opportunities, LLC | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 10,000,000 | |||||||||
Entasis Therapeutics Holdings Inc | Common stock and warrants | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Payments to acquire equity securities | $ 12,500 | $ 35,000 | ||||||||
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2021 | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Exercise price of warrants | $ / shares | $ 2 | |||||||||
Entasis Therapeutics Holdings Inc | Warrants acquired in third quarter of 2020 | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Exercise price of warrants | $ / shares | $ 2.675 | |||||||||
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2020 | ||||||||||
Subsidiary or Equity Method Investee [Line Items] | ||||||||||
Exercise price of warrants | $ / shares | $ 2.50 | |||||||||
Term of warrants | 5 years | 5 years |
Consolidated Entities and Acq_5
Consolidated Entities and Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Aug. 22, 2022 | Feb. 17, 2022 | Dec. 31, 2021 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 15,995 | $ 0 | ||
La Jolla Pharmaceutical Company | ||||
Business Acquisition [Line Items] | ||||
Cash and cash equivalents | $ 47,415 | |||
Short-term marketable securities | 471 | |||
Accounts receivable | 5,876 | |||
Inventory | 73,900 | |||
Prepaid expenses | 1,261 | |||
Other current assets | 907 | |||
Property and equipment, net | 13 | |||
Right of use assets | 226 | |||
Goodwill | 12,711 | |||
Intangible assets pertain to product rights and developed technologies | 152,500 | 152,500 | ||
Other assets | 710 | |||
Total assets acquired | 295,990 | |||
Accounts payable | 1,237 | |||
Deferred revenue, current | 2,849 | |||
Other accrued liabilities | 11,062 | |||
Other long-term liabilities | 74,283 | |||
Total liabilities assumed | 89,431 | |||
Total assets acquired, net | $ 206,559 | |||
Entasis Therapeutics Holdings Inc | ||||
Business Acquisition [Line Items] | ||||
Cash and cash equivalents | $ 23,070 | |||
Prepaid expenses | 5,554 | |||
Other current assets | 1,959 | |||
Property and equipment, net | 185 | |||
Right of use assets | 959 | |||
Goodwill | 3,284 | |||
Intangible assets pertain to product rights and developed technologies | $ 107,500 | 107,500 | ||
Other assets | 302 | |||
Total assets acquired | 142,813 | |||
Accounts payable | 1,583 | |||
Accrued personnel-related expenses | 1,057 | |||
Other current liabilities | 5,097 | |||
Deferred tax liabilities | 360 | |||
Total liabilities assumed | 8,097 | |||
Total assets acquired, net | $ 134,716 |
Consolidated Entities and Acq_6
Consolidated Entities and Acquisitions - Pro Forma Information (Details) - Entasis Therapeutics Holdings Inc - La Jolla Pharmaceutical Company - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Business Acquisition [Line Items] | ||||
Revenue | $ 72,830 | $ 111,176 | $ 292,077 | $ 347,696 |
Net income | 221,473 | 45,109 | 266,797 | 183,252 |
Net income attributable to Innoviva stockholders | $ 272,797 | $ 19,892 | $ 276,200 | $ 129,803 |
Consolidated Entities and Acq_7
Consolidated Entities and Acquisitions - ISP Fund LP (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Mar. 30, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | May 31, 2021 | |
CONSOLIDATED ENTITIES | |||||||
Total assets | $ 1,327,712 | $ 1,327,712 | $ 926,395 | ||||
Changes in fair values of equity and long-term investments | 130 | $ 33,613 | $ (67,881) | $ 133,973 | |||
ISP Fund LP | |||||||
CONSOLIDATED ENTITIES | |||||||
Distribution from partnership | $ 110,000 | ||||||
Economic interest of the Partnership (in percent) | 100% | ||||||
Total assets | 289,800 | $ 289,800 | 195,800 | ||||
Total liabilities | 200 | 200 | $ 200 | ||||
Investment-related expenses, net of investment-related income | 300 | 200 | 1,000 | 1,500 | |||
Changes in fair values of equity and long-term investments | $ (10,500) | $ 10,100 | $ (14,900) | $ 30,600 | |||
Capital contribution | $ 110,000 | ||||||
Lock-up period | 36 months |
Consolidated Entities and Acq_8
Consolidated Entities and Acquisitions - La Jolla Pharmaceutical Company (Details) - La Jolla Pharmaceutical Company - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | |
Aug. 22, 2022 | Sep. 30, 2022 | Sep. 30, 2022 | |
CONSOLIDATED ENTITIES | |||
Total consideration paid | $ 206.6 | ||
Acquisition share price | $ 6.23 | ||
Acquisition-related costs | $ 4.9 | $ 4.9 |
Financial Instruments and Fai_3
Financial Instruments and Fair Value Measurements - Equity Investment in Armata (Details) - Armata $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Feb. 09, 2022 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) Director | Dec. 31, 2021 USD ($) shares | Sep. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) $ / shares shares | Mar. 31, 2020 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) Director Tranche | Sep. 30, 2021 USD ($) | |
Equity investment | ||||||||
Number of tranches | Tranche | 2 | |||||||
Percentage of maximum voting rights | 49.50% | 49.50% | ||||||
Number of Investee's Board members currently representing the Company | Director | 3 | 3 | ||||||
Number of the Investee's Board members | Director | 8 | 8 | ||||||
Unrealized loss from fair value changes in equity investments | $ 11.6 | $ 35.3 | ||||||
Unrealized gain | $ 11.7 | $ 25.3 | ||||||
Special terms on re-designating board member to board of investee | In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata’s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata’s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata’s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata’s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement. | |||||||
Consolidated Investees [Member] | ||||||||
Equity investment | ||||||||
Equity method investment ownership percentage | 69.40% | 59.30% | 69.40% | |||||
Two Directors | ||||||||
Equity investment | ||||||||
Armata outstanding shares percentage | 12.50% | |||||||
Common stock and warrants | ||||||||
Equity investment | ||||||||
Amount of securities purchase agreement | $ 25 | |||||||
Equity and long-term investments at fair value | $ 156.4 | $ 146.7 | $ 156.4 | |||||
Warrants purchased in 2020 | ||||||||
Equity investment | ||||||||
Exercise price of warrants | $ / shares | $ 2.87 | |||||||
Term of warrants | 5 years | |||||||
Warrants purchased in 2021 | ||||||||
Equity investment | ||||||||
Exercise price of warrants | $ / shares | $ 3.25 | |||||||
Term of warrants | 5 years | |||||||
Warrants purchased in 2022 Member | ||||||||
Equity investment | ||||||||
Exercise price of warrants | $ / shares | $ 5 | |||||||
Term of warrants | 5 years | |||||||
Warrants | ||||||||
Equity investment | ||||||||
Number of warrants purchased under the securities purchase agreement | shares | 8,710,800 | |||||||
Equity and long-term investments at fair value | 50.6 | $ 58.6 | 50.6 | |||||
Common stock | ||||||||
Equity investment | ||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 1,212,122 | 8,710,800 | ||||||
Amount of securities purchase agreement | $ 4 | |||||||
Equity and long-term investments at fair value | $ 105.8 | $ 88.1 | $ 105.8 | |||||
Minimum [Member] | One Director | ||||||||
Equity investment | ||||||||
Armata outstanding shares percentage | 8% | |||||||
Maximum [Member] | One Director | ||||||||
Equity investment | ||||||||
Armata outstanding shares percentage | 12.50% | |||||||
Innoviva Strategic Opportunities, LLC | Common stock and warrants | ||||||||
Equity investment | ||||||||
Amount of securities purchase agreement | $ 45 | $ 20 | ||||||
Innoviva Strategic Opportunities, LLC | Warrants | ||||||||
Equity investment | ||||||||
Number of warrants to be purchased under the securities purchase agreement | shares | 4,500,000 | 6,153,847 | ||||||
Exercise price of warrants | $ / shares | $ 5 | |||||||
Innoviva Strategic Opportunities, LLC | Common stock | ||||||||
Equity investment | ||||||||
Number of shares to be purchased under the securities purchase agreement | shares | 9,000,000 | 6,153,847 |
Financial Instruments and Fai_4
Financial Instruments and Fair Value Measurements - Schedule of Income Statement Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | |
Equity Investment | ||||||||||
Net revenue | $ 67,257 | $ 97,862 | $ 265,536 | $ 284,186 | ||||||
Net Income | $ 229,347 | $ 21,371 | $ 37,858 | $ 102,646 | $ 110,846 | $ 109,695 | $ 288,576 | $ 323,187 | ||
Armata | ||||||||||
Equity Investment | ||||||||||
Net revenue | 1,883 | 1,168 | $ 4,108 | $ 2,738 | ||||||
Loss from operations | (9,220) | (6,196) | (24,043) | (18,084) | ||||||
Net Income | $ (9,215) | $ (6,194) | $ (24,036) | $ (18,313) |
Financial Instruments and Fai_5
Financial Instruments and Fair Value Measurements - Equity Investment in InCarda (Details) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Jun. 15, 2022 USD ($) $ / shares shares | Mar. 09, 2022 USD ($) | Sep. 30, 2022 USD ($) Director $ / shares | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) shares | Sep. 30, 2022 USD ($) Director $ / shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Equity Investment | |||||||||
Payments to acquire equity securities | $ 20,000,000 | ||||||||
InCarda | |||||||||
Equity Investment | |||||||||
Number of Investee's Board members currently representing the Company | Director | 1 | 1 | |||||||
Number of the Investee's Board members | Director | 8 | 8 | |||||||
Unrealized loss from fair value changes in equity investments | $ 8,800,000 | $ 600,000 | |||||||
Unrealized gain | $ 200,000 | $ 100,000 | |||||||
InCarda | Consolidated Investees [Member] | |||||||||
Equity Investment | |||||||||
Equity investment ownership percentage | 8.90% | 8.90% | 13% | ||||||
InCarda | Series C preferred stock and warrants | |||||||||
Equity Investment | |||||||||
Amount of securities purchase agreement | $ 15,800,000 | ||||||||
InCarda | Warrants | |||||||||
Equity Investment | |||||||||
Maximum number of additional shares into which warrants may be converted under the securities purchase agreement | shares | 5,117,358 | ||||||||
Equity and long-term investments at fair value | $ 400,000 | ||||||||
Exercise price of warrants | $ / shares | $ 0.7328 | $ 0.7328 | |||||||
Extended expiration date | Mar. 31, 2023 | ||||||||
InCarda | Convertible note and warrants | |||||||||
Equity Investment | |||||||||
Amount of securities purchase agreement | $ 700,000 | ||||||||
InCarda | Common stock | |||||||||
Equity Investment | |||||||||
Number of shares issued resulting from recapitalization of equity structure | shares | 4,093,886 | ||||||||
InCarda | Series A1 preferred stock | |||||||||
Equity Investment | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 37,350 | ||||||||
InCarda | Series D 1 Preferred Stock | |||||||||
Equity Investment | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 8,771,780 | ||||||||
InCarda | Series D 2 Preferred Stock | |||||||||
Equity Investment | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 3,369,802 | ||||||||
InCarda | Series D2 Warrants | |||||||||
Equity Investment | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,490,033 | ||||||||
Exercise price of warrants | $ / shares | $ 0.26 | ||||||||
InCarda | Series C preferred stock | |||||||||
Equity Investment | |||||||||
Number of shares issued resulting from recapitalization of equity structure | shares | 20,469,432 | ||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 5,117,358 | ||||||||
Transaction cost | $ 800,000 | ||||||||
Equity and long-term investments at fair value | $ 6,800,000 | $ 6,800,000 | 15,800,000 | ||||||
Impairment of equity investments | 9,000,000 | $ 0 | |||||||
Exercise price of warrants | $ / shares | $ 0.73 | ||||||||
InCarda | Series C Warrants and Series D Warrants | |||||||||
Equity Investment | |||||||||
Equity and long-term investments at fair value | 500,000 | 500,000 | |||||||
InCarda | Series D Preferred Stock | |||||||||
Equity Investment | |||||||||
Payments to acquire equity securities | $ 2,300,000 | ||||||||
InCarda | Series D1 Preferred Stock, Series D2 Preferred Stock and Common Stock | |||||||||
Equity Investment | |||||||||
Equity and long-term investments at fair value | $ 3,200,000 | $ 3,200,000 | |||||||
InCarda | Significant Unobservable Inputs, Level 3 | Backsolve Valuation | |||||||||
Equity Investment | |||||||||
Expected holding period | 2 years | ||||||||
Risk free interest rate | 3.20% | ||||||||
Dividend yield | 0% | ||||||||
Estimated volatility | 122% | ||||||||
InCarda Convertible Note | |||||||||
Equity Investment | |||||||||
Debt Instrument, annual interest rate | 6% | ||||||||
Gross Proceeds from sale of equity | $ 10,000,000 | ||||||||
Debt instrument principal amount percentage | 100% |
Financial Instruments and Fai_6
Financial Instruments and Fair Value Measurements - Equity Investment in ImaginAb (Details) - ImaginAb $ in Millions | 3 Months Ended | ||
Mar. 31, 2021 USD ($) shares | Sep. 30, 2022 USD ($) Director | Dec. 31, 2021 USD ($) | |
Equity Investment | |||
Transaction costs to acquire equity securities | $ 0.4 | ||
Number of Investee's Board members currently representing the Company | Director | 1 | ||
Number of the Investee's Board members | Director | 5 | ||
Equity and long-term investments at fair value | $ 6.4 | $ 6.4 | |
Consolidated Investees [Member] | |||
Equity Investment | |||
Equity investment ownership percentage | 11.50% | 14.50% | |
Series C preferred stock | |||
Equity Investment | |||
Number of shares to be purchased under the securities purchase agreement | shares | 4,051,724 | ||
Amount of securities purchase agreement | $ 4.7 | ||
One of ImaginAb's Common Stockholders | Common stock | |||
Equity Investment | |||
Number of shares to be purchased under the securities purchase agreement | shares | 4,097,157 | ||
Amount of securities purchase agreement | $ 1.3 |
Financial Instruments and Fai_7
Financial Instruments and Fair Value Measurements - Convertible Promissory Note in Gate Neuroscience (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 USD ($) Director | Dec. 31, 2021 USD ($) | Sep. 30, 2022 USD ($) Director | |
Equity Investment | |||
Equity and long-term investments | $ 489,111 | $ 483,845 | $ 489,111 |
Gate Neuroscience Member | |||
Equity Investment | |||
Number Of Common Stock Issued Description | The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the “Capped Conversion Price”) and the qualified event price (the “Qualified Event Price”). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing. | ||
Equity and long-term investments | 15,400 | $ 15,100 | 15,400 |
Unrealized gain from fair value changes in equity investments | $ 200 | $ 300 | |
Number of Investee's Board members currently representing the Company | Director | 1 | 1 | |
Number of the Investee's Board members | Director | 3 | 3 | |
Convertible Promissory Note Purchase Agreement | Gate Neuroscience Member | |||
Equity Investment | |||
Convertable notes Face Value | $ 15,000 | ||
Debt Instrument, Interest Rate, Effective Percentage | 8% |
Financial Instruments and Fai_8
Financial Instruments and Fair Value Measurements - Equity Investment in Nanolive (Details) - Nanolive SFr in Millions, $ in Millions | Feb. 18, 2022 USD ($) shares | Feb. 18, 2022 CHF (SFr) shares | Sep. 30, 2022 USD ($) Director |
Equity Investment | |||
Transaction costs to acquire equity securities | $ | $ 0.7 | ||
Number of Investee's Board members currently representing the Company | Director | 1 | ||
Number of the Investee's Board members | Director | 7 | ||
Fair value of equity securities | $ | $ 10.6 | ||
Consolidated Investees [Member] | |||
Equity Investment | |||
Equity investment ownership percentage | 15.50% | ||
Series C preferred stock | |||
Equity Investment | |||
Number of shares to be purchased under the securities purchase agreement | shares | 18,750,000 | 18,750,000 | |
Amount of securities purchase agreement | $ 9.8 | SFr 9 |
Financial Instruments and Fai_9
Financial Instruments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Dec. 31, 2021 | |||
Fair Value Measurements | ||||
Contingent value rights | $ 294 | |||
ISP Fund LP | ||||
Liabilities | ||||
Lock-up period | 36 months | 36 months | ||
Contributed to partnership for investing | $ 300,000 | |||
Cash | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 5,100 | |||
Money market funds | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 38,700 | $ 3,500 | ||
Equity investment | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 246,000 | 192,200 | ||
Private Placement Positions and Convertible Notes | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 53,200 | |||
Recurring basis | ||||
Assets | ||||
Total assets measured at estimated fair value | 730,926 | 606,792 | ||
Recurring basis | Money market funds | ||||
Assets | ||||
Total assets measured at estimated fair value | 261,718 | 145,132 | ||
Recurring basis | Short-term marketable securities | ||||
Assets | ||||
Total assets measured at estimated fair value | 282 | |||
Recurring basis | Equity investments and money market funds | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 289,787 | [1] | 195,745 | [2] |
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | ||||
Assets | ||||
Total assets measured at estimated fair value | 604,448 | 489,704 | ||
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds | ||||
Assets | ||||
Total assets measured at estimated fair value | 261,718 | 145,132 | ||
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Short-term marketable securities | ||||
Assets | ||||
Total assets measured at estimated fair value | 282 | |||
Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and money market funds | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 236,624 | [1] | 193,677 | [2] |
Recurring basis | Significant Other Observable Inputs, Level 2 | ||||
Assets | ||||
Total assets measured at estimated fair value | 50,605 | 99,509 | ||
Recurring basis | Significant Unobservable Inputs, Level 3 | ||||
Assets | ||||
Total assets measured at estimated fair value | 75,873 | 17,579 | ||
Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and money market funds | ISP Fund LP | ||||
Assets | ||||
Total assets measured at estimated fair value | 53,163 | [1] | 2,068 | [2] |
Nonrecurring basis | ||||
Fair Value Measurements | ||||
Contingent value rights | 294 | |||
Liabilities | ||||
Total liabilities measured at estimated fair value | 482,577 | |||
Nonrecurring basis | Debt | ||||
Fair Value Measurements | ||||
2023 Notes | 95,001 | 261,769 | ||
2025 Notes | 185,041 | 234,498 | ||
2028 Notes | 202,241 | |||
Total fair value of debt | 482,283 | 496,267 | ||
Nonrecurring basis | Significant Other Observable Inputs, Level 2 | ||||
Liabilities | ||||
Total liabilities measured at estimated fair value | 482,283 | |||
Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Debt | ||||
Fair Value Measurements | ||||
2023 Notes | 95,001 | 261,769 | ||
2025 Notes | 185,041 | 234,498 | ||
2028 Notes | 202,241 | |||
Total fair value of debt | 482,283 | 496,267 | ||
Nonrecurring basis | Significant Unobservable Inputs, Level 3 | ||||
Fair Value Measurements | ||||
Contingent value rights | 294 | |||
Liabilities | ||||
Total liabilities measured at estimated fair value | 294 | |||
Armata | Recurring basis | Equity investment | Common stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 105,824 | 88,101 | ||
Armata | Recurring basis | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 50,605 | 58,595 | ||
Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 105,824 | 88,101 | ||
Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 50,605 | 58,595 | ||
Entasis Therapeutics Holdings Inc | Recurring basis | Equity investment | Common stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 62,794 | |||
Entasis Therapeutics Holdings Inc | Recurring basis | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 40,914 | |||
Entasis Therapeutics Holdings Inc | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 62,794 | |||
Entasis Therapeutics Holdings Inc | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 40,914 | |||
InCarda | Recurring basis | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 411 | |||
InCarda | Recurring basis | Equity investment | Series C preferred stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 6,809 | |||
InCarda | Recurring basis | Equity investment | Preferred Stock Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 501 | |||
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 411 | |||
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Series C preferred stock | ||||
Assets | ||||
Total assets measured at estimated fair value | 6,809 | |||
InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Preferred Stock Warrants | ||||
Assets | ||||
Total assets measured at estimated fair value | 501 | |||
Gate Neuroscience Member | Recurring basis | Convertible Debt Member | ||||
Assets | ||||
Total assets measured at estimated fair value | 15,400 | 15,100 | ||
Gate Neuroscience Member | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible Debt Member | ||||
Assets | ||||
Total assets measured at estimated fair value | $ 15,400 | $ 15,100 | ||
[1] The investments held by ISP Fund LP, consisted of $ 246.0 million in equity investments, which included private placement positions and convertible notes of $ 53.2 million, $ 38.7 million in money market funds and $ 5.1 million in cash. Our total capital contribution of $ 300.0 million is subject to a 36-month lock-up period from the date of such capital contributions. The investments held by ISP Fund LP, consisted of $ 192.2 million equity investments and $ 3.5 million money market funds, are subject to a 36 -month lock-up period from our initial contribution date, December 11, 2020. |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets (Additional Information) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Aug. 22, 2022 | Feb. 17, 2022 | Dec. 31, 2021 | |
Goodwill [Line Items] | |||||||
Goodwill | $ 15,995 | $ 15,995 | $ 0 | ||||
Amortization expense | 1,511 | $ 0 | 1,511 | $ 0 | |||
In-process research and development | Collaboration agreement | |||||||
Goodwill [Line Items] | |||||||
Amortization expense | 0 | ||||||
La Jolla Pharmaceutical Company | |||||||
Goodwill [Line Items] | |||||||
Goodwill | $ 12,711 | ||||||
Future amortization expense, remainder of 2022 | 3,500 | 3,500 | |||||
Future amortization expense, 2023 | 13,800 | 13,800 | |||||
Future amortization expense, 2024 | 13,800 | 13,800 | |||||
Future amortization expense, 2025 | 13,800 | 13,800 | |||||
Future amortization expense, 2026 | 13,800 | 13,800 | |||||
Future amortization expense, thereafter | 78,000 | 78,000 | |||||
Intangible assets pertain to product rights and developed technologies | 152,500 | 152,500 | $ 152,500 | ||||
Entasis Therapeutics Holdings Inc | |||||||
Goodwill [Line Items] | |||||||
Goodwill | $ 3,284 | ||||||
Intangible assets pertain to product rights and developed technologies | 107,500 | 107,500 | $ 107,500 | ||||
Entasis Therapeutics Holdings Inc | Collaboration agreement | |||||||
Goodwill [Line Items] | |||||||
Intangible assets pertain to product rights and developed technologies | 35,400 | 35,400 | |||||
Entasis Therapeutics Holdings Inc | In-process research and development | |||||||
Goodwill [Line Items] | |||||||
Intangible assets pertain to product rights and developed technologies | $ 72,100 | $ 72,100 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||
Marketed products, gross carrying amount | $ 152,500 | |
In-process research and development, gross carrying amount | 72,100 | |
Collaboration agreement, gross carrying amount | 35,400 | |
Total gross carrying amount | 260,000 | |
Marketed products, Accumulated amortization | (1,511) | |
Accumulated amortization | (1,511) | |
Marketed products, net carrying amount | 150,989 | |
In-process research and development, net carrying amount | 72,100 | |
Collaboration agreement, net carrying amount | 35,400 | |
Net carrying amount | $ 258,489 | $ 0 |
Maximum [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Marketed products, Useful Life | 10 years | |
Minimum [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Marketed products, Useful Life | 8 years |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 5,757 | |
Work-in-process | 54,126 | |
Finished goods | 10,924 | |
Total inventory | $ 70,807 | $ 0 |
Balance Sheet Components - Sc_2
Balance Sheet Components - Schedule of Other Accrued Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Balance Sheet Related Disclosures [Abstract] | ||
Accrued contract manufacturing expenses | $ 5,319 | $ 0 |
Accrued clinical expenses | 1,062 | 0 |
Accrued research expenses | 692 | 0 |
Accrued professional services | 3,542 | 894 |
Current portion of lease liabilities | 1,170 | 106 |
Accrued license fees and royalties | 1,155 | 0 |
Other | 2,180 | 9 |
Total other accrued liabilities | $ 15,120 | $ 1,009 |
Balance Sheet Components (Addit
Balance Sheet Components (Additional Information) (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Inventory [Line Items] | |||
Other long-term liabilities | $ 78,421,000 | $ 78,421,000 | $ 0 |
La Jolla Pharmaceutical Company | |||
Inventory [Line Items] | |||
Inventory | $ 0 | ||
Net fair value adjustment of inventory | 64,100,000 | 64,100,000 | |
Amortization of fair value adjustments of Cost of products sold | $ 2,700,000 | $ 2,700,000 |
Balance Sheet Component - Sched
Balance Sheet Component - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Balance Sheet Related Disclosures [Abstract] | ||
Long-term portion of lease liabilities | $ 2,703 | $ 0 |
Deferred royalty obligation | 75,424 | |
Contingent Value rights liability | 294 | |
Total other long-term liabilities | $ 78,421 | $ 0 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Stock-based compensation | ||||
Total stock-based compensation expense | $ 3,717 | $ 542 | $ 6,021 | $ 1,463 |
Selling, general and administrative | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | 2,422 | 542 | 4,240 | 1,463 |
Research and development | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | $ 1,295 | $ 0 | $ 1,781 | $ 0 |
Stock-Based Compensation - Valu
Stock-Based Compensation - Valuation Assumptions (Details) - $ / shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Valuation Assumptions | ||||
Granted (in shares) | 0 | 0 | ||
Stock options | Innoviva [Member] | Weighted-average | ||||
Valuation Assumptions | ||||
Expected term (in years) | 6 years | |||
Volatility | 45% | |||
Dividend yield | 0% | 0% | ||
Weighted-average estimated fair value of stock options granted | $ 5.61 | |||
Stock options | Innoviva [Member] | Minimum | ||||
Valuation Assumptions | ||||
Risk-free interest rate | 1.60% | 1.07% | ||
Expected term (in years) | 5 years 6 months | |||
Volatility | 38.80% | |||
Weighted-average estimated fair value of stock options granted | $ 6.98 | |||
Stock options | Innoviva [Member] | Maximum | ||||
Valuation Assumptions | ||||
Risk-free interest rate | 3.03% | 1.13% | ||
Expected term (in years) | 6 years 1 month 9 days | |||
Volatility | 40.50% | |||
Weighted-average estimated fair value of stock options granted | $ 7.73 |
Debt - Summary (Details)
Debt - Summary (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Sep. 30, 2022 | Apr. 18, 2022 | Mar. 07, 2022 | Dec. 31, 2021 | |
Debt | ||||
Total debt | $ 549,704 | $ 433,484 | ||
Less: Unamortized debt discount and issuance costs | (9,894) | (38,831) | ||
Total debt, net | 539,810 | 394,653 | ||
Less: Current portion of long-term debt, net | 96,131 | 0 | ||
Total long-term debt, net | 443,679 | 394,653 | ||
Deferred royalty obligation | $ 75,424 | |||
HealthCare Royalty Partners | ||||
Debt | ||||
Maximum potential royalty payout | 14% | |||
Increase in maximum potential payout percent | 4% | |||
Maximum aggregate royalty payments | $ 225,000 | |||
Required payment for breach of agreement, payment one | 125,000 | |||
Payment for royalty agreement | 11,600 | |||
2023 Notes | Convertible subordinated notes | ||||
Debt | ||||
Total debt | 96,204 | $ 96,200 | $ 96,200 | 240,984 |
Less: Unamortized debt discount and issuance costs | (73) | $ 200 | (620) | |
2025 Notes | ||||
Debt | ||||
Unamortized debt discount | 67,300 | |||
2025 Notes | Convertible senior notes | ||||
Debt | ||||
Total debt | 192,500 | 192,500 | ||
Less: Unamortized debt discount and issuance costs | (2,092) | (38,211) | ||
2028 Notes | Convertible senior notes | ||||
Debt | ||||
Total debt | 261,000 | $ 0 | ||
Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners | ||||
Debt | ||||
Interest expense | 1,500 | |||
Deferred royalty obligation | 79,900 | |||
Unamortized debt discount | 500 | |||
Royalty Obligation Payable | 75,400 | |||
Short term accrued interest | 4,500 | |||
Royalty Payments | $ 1,000 |
Debt - Convertible Subordinated
Debt - Convertible Subordinated Notes (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||
Apr. 18, 2022 USD ($) | Mar. 07, 2022 USD ($) | Jul. 31, 2014 $ / shares $ / Item | Jul. 31, 2014 $ / shares $ / Item shares | Jan. 31, 2013 USD ($) Item $ / shares $ / Item shares | Sep. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2016 USD ($) | |
Debt | ||||||||||||
Payment for repurchase of debt instrument | $ 165,131,000 | $ 0 | ||||||||||
Accrued interest payable | $ 5,702,000 | 5,702,000 | $ 4,152,000 | |||||||||
Loss on extinguishment of debt | 0 | $ 0 | (20,662,000) | 0 | ||||||||
Principal | 549,704,000 | 549,704,000 | 433,484,000 | |||||||||
Debt discount and issuance costs, net | (9,894,000) | $ (9,894,000) | (38,831,000) | |||||||||
2023 Notes | Privately-negotiated capped call option | ||||||||||||
Debt | ||||||||||||
Cap price for the underlying number of shares (in dollars per share) | $ / Item | 27.04 | 27.04 | ||||||||||
2023 Notes | Convertible subordinated notes | ||||||||||||
Debt | ||||||||||||
Loan amount | $ 287,500,000 | |||||||||||
Debt instrument maturity date | Jan. 15, 2023 | |||||||||||
Proceeds from issuance of notes payable, net of debt issuance costs | $ 281,200,000 | |||||||||||
Debt Instrument, annual interest rate | 2.125% | |||||||||||
Initial conversion, shares per $1,000 principal amount | shares | shares | 35.9903 | |||||||||||
Adjusted conversion, shares per $1,000 principal amount | shares | 50.5818 | |||||||||||
Conversion price of convertible notes into common stock (in dollars per share) | $ / shares | $ 27.79 | |||||||||||
Ratio of repurchase price to the principal amount | 100% | |||||||||||
Portion of debt retired, face value | $ 144,800,000 | $ 144,800,000 | $ 14,100,000 | |||||||||
Portion of debt retired, carrying value | 144,500,000 | $ 13,900,000 | ||||||||||
Payment for repurchase of debt instrument | $ 165,600,000 | $ 165,600,000 | ||||||||||
Percentage of notes repurchased | 60% | |||||||||||
Accrued interest payable | $ 400,000 | |||||||||||
Unamortized debt issuance cost | 300,000 | |||||||||||
Loss on extinguishment of debt | 20,700,000 | |||||||||||
Principal | $ 96,200,000 | 96,200,000 | 96,204,000 | $ 96,204,000 | 240,984,000 | |||||||
Debt discount and issuance costs, net | $ 200,000 | (73,000) | (73,000) | (620,000) | ||||||||
Net Carrying Amount | 96,131,000 | 96,131,000 | $ 240,364,000 | |||||||||
Interest expense | ||||||||||||
Contractual interest expense | 511,000 | 1,280,000 | 2,106,000 | 3,840,000 | ||||||||
Amortization of debt issuance costs | 59,000 | 143,000 | 240,000 | 431,000 | ||||||||
Total interest and amortization expense | $ 570,000 | $ 1,423,000 | $ 2,346,000 | $ 4,271,000 | ||||||||
2023 Notes | Convertible subordinated notes | Privately-negotiated capped call option | ||||||||||||
Debt | ||||||||||||
Payments for capped call options | $ 36,800,000 | |||||||||||
Number of derivative instruments purchased | Item | 2 | |||||||||||
Capped call strike price | $ / shares | $ 19.77 | $ 19.77 | ||||||||||
Strike price for the underlying number of shares (in dollars per share) | $ / shares | $ 27.79 | $ 19.77 | $ 27.79 | |||||||||
Cap price for the underlying number of shares (in dollars per share) | $ / Item | 38 | 38 | 38 | |||||||||
2023 Notes | Convertible subordinated notes | Stock prices above $38.00 per share | Maximum | ||||||||||||
Debt | ||||||||||||
Net shares settlement payable to the entity | shares | 2,779,659 | |||||||||||
2023 Notes | Convertible subordinated notes | Stock prices below $27.79 per share | Minimum | ||||||||||||
Debt | ||||||||||||
Net shares settlement payable to the entity | shares | 0 | |||||||||||
2023 Notes | Old Rate [Member] | Convertible subordinated notes | ||||||||||||
Debt | ||||||||||||
Effective interest rate | 2.36% | |||||||||||
2023 Notes | New Rate [Member] | Convertible subordinated notes | ||||||||||||
Debt | ||||||||||||
Effective interest rate | 2.37% | |||||||||||
Innoviva's Common Stock | 2023 Notes | Convertible subordinated notes | ||||||||||||
Debt | ||||||||||||
Notes converted into common stock, Amount | $ 3,000 |
Debt - Convertible Senior Notes
Debt - Convertible Senior Notes (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
Aug. 07, 2017 USD ($) $ / shares | Jan. 31, 2013 USD ($) $ / shares $ / Item | Sep. 30, 2022 USD ($) $ / shares | Mar. 31, 2022 USD ($) $ / shares $ / Item | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) $ / shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Apr. 18, 2022 USD ($) | Mar. 07, 2022 USD ($) | Jan. 01, 2022 | Aug. 01, 2017 $ / shares | Dec. 31, 2016 USD ($) | Jul. 31, 2014 $ / Item | |
Debt | ||||||||||||||
Principal | $ 549,704 | $ 549,704 | $ 433,484 | |||||||||||
Debt discount and issuance costs, net | (9,894) | $ (9,894) | (38,831) | |||||||||||
2023 Notes | Privately-negotiated capped call option | ||||||||||||||
Debt | ||||||||||||||
Cap price for the underlying number of shares (in dollars per share) | $ / Item | 27.04 | |||||||||||||
2025 Notes | ||||||||||||||
Debt | ||||||||||||||
Unamortized debt discount | 67,300 | |||||||||||||
Common stock price to current conversion price ratio | 130% | |||||||||||||
Average trading price percentage | 98% | |||||||||||||
Total issuance costs | 5,400 | |||||||||||||
Liability issuance costs | 3,500 | |||||||||||||
Equity issuance costs | $ 1,900 | |||||||||||||
Effective interest rate | 8.87% | |||||||||||||
2025 Notes | ASU 2020-06 | ||||||||||||||
Debt | ||||||||||||||
Effective interest rate | 2.88% | |||||||||||||
2025 Notes | Common stock | ||||||||||||||
Debt | ||||||||||||||
Share Price | $ / shares | $ 13.28 | |||||||||||||
2028 Notes | ||||||||||||||
Debt | ||||||||||||||
Debt instrument, covenant terms description | The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately. | |||||||||||||
Convertible senior notes | 2025 Notes | ||||||||||||||
Debt | ||||||||||||||
Ratio of repurchase price to the principal amount | 100% | |||||||||||||
Principal | 192,500 | $ 192,500 | $ 192,500 | |||||||||||
Debt discount and issuance costs, net | (2,092) | (2,092) | (38,211) | |||||||||||
Net Carrying Amount | 190,408 | 190,408 | 154,289 | |||||||||||
Equity component, net | 0 | 0 | 65,361 | |||||||||||
Interest expense | ||||||||||||||
Contractual interest expense | 1,203 | $ 1,203 | 3,609 | $ 3,609 | ||||||||||
Amortization of debt issuance costs | 174 | 166 | 517 | 487 | ||||||||||
Amortization of debt discount | 0 | 1,997 | 0 | 5,859 | ||||||||||
Total interest and amortization expense | $ 1,377 | 3,366 | $ 4,126 | 9,955 | ||||||||||
Convertible senior notes | 2025 Notes | Over-Allotment Option | ||||||||||||||
Debt | ||||||||||||||
Loan amount | $ 17,500 | |||||||||||||
Convertible senior notes | 2025 Notes | Private Placement | ||||||||||||||
Debt | ||||||||||||||
Loan amount | $ 192,500 | |||||||||||||
Debt Instrument, annual interest rate | 2.50% | |||||||||||||
Convertible senior notes | 2025 Notes | Common stock | ||||||||||||||
Debt | ||||||||||||||
Conversion rate for shares of common stock per $1,000 principal | 57.9240 | |||||||||||||
Conversion price (dollars per share) | $ / shares | $ 17.26 | $ 17.26 | $ 17.26 | |||||||||||
Debt instrument maturity date | Aug. 15, 2025 | |||||||||||||
Conversion premium (as a percent) | 30% | |||||||||||||
Convertible senior notes | 2028 Notes | ||||||||||||||
Debt | ||||||||||||||
Loan amount | $ 261,000 | |||||||||||||
Debt instrument maturity date | Mar. 15, 2028 | |||||||||||||
Proceeds from issuance of convertible notes, net of issuance costs | $ 252,600 | |||||||||||||
Common stock price to current conversion price ratio | 130% | |||||||||||||
Average trading price percentage | 98% | |||||||||||||
Ratio of repurchase price to the principal amount | 100% | |||||||||||||
Effective interest rate | 2.70% | 2.70% | ||||||||||||
Principal | $ 261,000 | $ 261,000 | 0 | |||||||||||
Debt issuance costs | (7,729) | (7,729) | ||||||||||||
Net Carrying Amount | 253,271 | 253,271 | ||||||||||||
Interest expense | ||||||||||||||
Contractual interest expense | 1,371 | 3,127 | ||||||||||||
Amortization of debt issuance costs | 328 | 735 | ||||||||||||
Total interest and amortization expense | 1,699 | $ 3,862 | ||||||||||||
Convertible senior notes | 2028 Notes | Privately-negotiated capped call option | ||||||||||||||
Debt | ||||||||||||||
Cap price for the underlying number of shares (in dollars per share) | $ / Item | 33.9850 | |||||||||||||
Purchases of capped calls in connection with convertible senior notes due 2028 | $ 21,000 | |||||||||||||
Convertible senior notes | 2028 Notes | Over-Allotment Option | ||||||||||||||
Debt | ||||||||||||||
Loan amount | 45,000 | |||||||||||||
Portion of debt instrument face amount, Exercised | $ 36,000 | |||||||||||||
Convertible senior notes | 2028 Notes | Private Placement | ||||||||||||||
Debt | ||||||||||||||
Debt Instrument, annual interest rate | 2.125% | |||||||||||||
Convertible senior notes | 2028 Notes | Common stock | ||||||||||||||
Debt | ||||||||||||||
Conversion rate for shares of common stock per $1,000 principal | 38.1432 | |||||||||||||
Conversion price (dollars per share) | $ / shares | $ 26.22 | |||||||||||||
Convertible subordinated notes | 2023 Notes | ||||||||||||||
Debt | ||||||||||||||
Loan amount | $ 287,500 | |||||||||||||
Debt Instrument, annual interest rate | 2.125% | |||||||||||||
Conversion price (dollars per share) | $ / shares | $ 27.79 | |||||||||||||
Debt instrument maturity date | Jan. 15, 2023 | |||||||||||||
Ratio of repurchase price to the principal amount | 100% | |||||||||||||
Debt Instrument, Repurchased Face Amount | $ 144,800 | $ 144,800 | $ 14,100 | |||||||||||
Principal | 96,204 | $ 96,204 | 240,984 | $ 96,200 | 96,200 | |||||||||
Debt discount and issuance costs, net | (73) | (73) | $ (620) | $ 200 | ||||||||||
Interest expense | ||||||||||||||
Contractual interest expense | 511 | 1,280 | 2,106 | 3,840 | ||||||||||
Amortization of debt issuance costs | 59 | 143 | 240 | 431 | ||||||||||
Total interest and amortization expense | $ 570 | $ 1,423 | $ 2,346 | $ 4,271 | ||||||||||
Convertible subordinated notes | 2023 Notes | Privately-negotiated capped call option | ||||||||||||||
Debt | ||||||||||||||
Cap price for the underlying number of shares (in dollars per share) | $ / Item | 38 | 38 |
Debt - Debt Maturities (Details
Debt - Debt Maturities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Long-term debt maturities for years ending December 31: | ||
Remainder of 2022 | $ 0 | |
2023 | 96,204 | |
2024 | 0 | |
2025 | 192,500 | |
2026 | 0 | |
Thereafter | 261,000 | |
Total | $ 549,704 | $ 433,484 |
Commitments and Contingencies_2
Commitments and Contingencies (Additional Information) (Details) | Sep. 30, 2022 |
Lessee, Lease, Description [Line Items] | |
Weighted average discount rate | 7.50% |
Operating lease, Weighted average remaining lease term | 3 years |
Commitments and Contingencies -
Commitments and Contingencies - Schedule of Components of Lease Cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2022 | Sep. 30, 2022 | |
Lease, Cost [Abstract] | ||
Straight line operating lease costs | $ 640 | $ 1,101 |
Variable lease costs | 35 | 110 |
Total lease costs | $ 675 | $ 1,211 |
Commitments and Contingencies_3
Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |
Cash paid for amounts included in the measurement of operating lease liabilities: | $ 540 |
Operating lease right-of-use assets obtained in exchange for operating lease obligations | 3,323 |
Right-of-use assets obtained through acquisitions | $ 1,185 |
Commitments and Contingencies_4
Commitments and Contingencies - Schedule of Operating Lease Information Presented In Balance Sheet (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases, Operating [Abstract] | ||
Right-of-use assets | $ 3,679 | $ 97 |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Liabilities, Current | Liabilities, Current |
Current portion of lease liabilities | $ 1,170 | $ 106 |
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent |
Long-term portion of lease liabilities | $ 2,703 | $ 0 |
Total operating lease liabilities | $ 3,873 | $ 106 |
Commitments and Contingencies_5
Commitments and Contingencies (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Commitments and Contingencies Disclosure [Abstract] | ||
Remainder of 2022 | $ 250 | |
2023 | 1,542 | |
2024 | 1,269 | |
2025 | 1,289 | |
Total | 4,350 | |
Less: imputed interest | (477) | |
Total operating lease liabilities | $ 3,873 | $ 106 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | ||||
Provisional income tax expense | $ 57,077 | $ 20,531 | $ 63,061 | $ 65,600 |
Effective tax rate (as a percent) | 18.30% | 16.90% |